Elithair’s hair loss news

Researchers have developed a flexible, textile-based wearable device that uses near-infrared OLED light to stimulate hair follicles without drugs. Tuned specifically to activate human dermal papilla cells, the fabric showed strong anti-ageing and cell-migration effects in laboratory tests, outperforming standard red-light therapy. The device is waterproof, bendable and produces minimal heat, making it suitable for everyday wear. While still in early stages, this innovation could pave the way for non-invasive, wearable hair loss treatments in the UK.

Nearly half of patients with severe alopecia areata achieved meaningful hair regrowth after switching to a second JAK inhibitor, according to a new US study. Those who had previously responded to a JAK inhibitor were over three times more likely to benefit from switching. While some mild side effects were reported, results suggest changing JAK treatments could help patients who lose response over time. For UK clinicians and patients navigating limited options for severe alopecia areata, the findings support a more flexible, personalised treatment approach.

A six-month clinical trial has found that a proprietary saw palmetto extract significantly improved hair growth in adults with self-perceived thinning hair. Compared with placebo, participants taking the supplement saw notable increases in terminal hair count, vellus hair count and overall hair density, with particularly strong results in men and menopausal women. Importantly, no treatment-related side effects were reported. For UK readers interested in natural, non-prescription approaches to thinning hair, this study suggests saw palmetto could be a safe and effective option worth watching.

New research suggests severe alopecia areata is linked to widespread immune system activation, not just hair follicle damage. Patients with extensive hair loss showed significantly higher levels of systemic inflammatory markers compared with those with mild disease and healthy individuals. Importantly, these markers fell as patients improved on JAK inhibitor treatment, alongside visible hair regrowth. While not yet ready for routine NHS use as monitoring tools, the findings support the idea that severe alopecia areata is a whole-body inflammatory condition and that successful treatment may calm this broader immune response.

A phase 3 trial has shown that deuruxolitinib, an oral JAK inhibitor, significantly improves scalp hair regrowth in adults with severe alopecia areata. After 24 weeks, up to 38% of patients achieved near-complete scalp coverage, compared with less than 1% on placebo. Improvements were seen as early as 12 weeks, even in those with very extensive hair loss. The treatment was generally well tolerated, with mostly mild to moderate side effects. These results position deuruxolitinib as a promising new systemic option for severe alopecia areata.

A 12-month study has found that low-level laser therapy (LLLT) can deliver sustained improvements for people with androgenetic alopecia. Using a home helmet-style device three times a week, participants saw a 25% rise in hair density and a 15% increase in hair thickness, with benefits continuing throughout the year. Results were consistent in both men and women and across mild to severe hair loss. No treatment-related side effects were reported, reinforcing LLLT’s appeal as a safe, non-drug or add-on option for long-term hair loss management.

New genetic research suggests certain blood metabolites may play a causal role in alopecia areata. Using Mendelian randomisation data from European populations, researchers found higher levels of glucose, citric acid and cholesterol-related lipids were linked to increased AA risk, while glutamine appeared protective. Importantly, no evidence of reverse causation was found. While not ready to guide treatment, the findings could help shape future research into metabolic and dietary factors influencing autoimmune hair loss.

A large international study suggests that people with alopecia areata who take JAK inhibitors may be less likely to develop major depressive disorder or need antidepressants. Analysing data from over 36,000 patients, researchers found JAK inhibitor users had around a 50% lower risk of depression and significantly reduced antidepressant use, with benefits lasting up to 10 years. Given the high emotional toll of hair loss, these findings highlight potential mental health benefits alongside hair regrowth, although disease severity data was not available.

A new case report highlights that scarring alopecia can occur even in localized dystrophic epidermolysis bullosa (DEB), a rare genetic skin-fragility disorder. A 58-year-old woman developed progressive hair thinning resembling lichen planopilaris (LPP), but biopsies showed overlapping features of both conditions. The review shows scarring alopecia is under-recognised in DEB and may stem from chronic skin fragility, inflammation, or inherent collagen defects. Authors urge early scalp monitoring and biopsy in DEB patients, as distinguishing DEB-related hair loss from primary inflammatory alopecias is crucial for treatment.

A large population study has found that metabolic dysfunction–associated steatotic liver disease (MASLD) significantly increases the risk of androgenetic alopecia (AGA), especially in women. Poor lifestyle habits — high carbohydrate intake, low exercise, or not taking lipid-lowering medication — further heightened the association. The findings suggest AGA may act as an early warning sign of underlying metabolic issues, highlighting the need for clinicians to consider liver and metabolic screening, particularly in women with early or unexpected hair thinning.

New research suggests alopecia areata may be driven by systemic inflammation rather than scalp-only immune activity. While JAK inhibitors remain the mainstay treatment, experts say additional therapies that lower whole-body inflammation — such as low-dose oral minoxidil and GLP-1 weight-loss drugs — may enhance results and prolong remission. Early treatment appears crucial, as stopping JAK inhibitors too soon often triggers relapse. Growing evidence indicates systemic inflammation could influence other inflammatory hair disorders, potentially including post-stress hair loss seen after COVID.

New research suggests that ritlecitinib—a JAK3/TEC inhibitor already approved for severe alopecia areata—may also help reverse forms of scarring alopecia once thought permanent. Studies show that inflammation, not just fibrosis, drives these conditions, and that ritlecitinib can suppress key immune pathways while reactivating hair-forming genes. Patients treated within the first few years of disease showed the strongest regrowth, highlighting the importance of early intervention. Molecular changes closely matched visible improvements, raising hopes that targeted JAK3 inhibition could become a future option for UK patients with otherwise untreatable autoimmune hair loss.

A major clinical trial published in the British Journal of Dermatology reports that Cinainu—a topical botanical drug made from four plant extracts—successfully promotes hair regrowth in children and adolescents with moderate to severe alopecia areata. Unlike JAK inhibitors, Cinainu achieved meaningful improvements without immunosuppression-related side-effects and maintained benefits even after treatment stopped. Nearly half of treated patients reached strong regrowth by week 48. The treatment was well-tolerated and even outperformed placebo on quality-of-life measures. With global regulators now considering Phase 3 trials, Cinainu may become a safer early-stage option for young people with autoimmune hair loss.

New research using advanced 3D imaging of human scalp follicles grown ex vivo has revealed that hair growth may be driven not just by cell division in the bulb, but by a previously unrecognised “pulling” action from the outer root sheath (ORS). Scientists observed helical downward movement of ORS cells and strong upward flow in the inner hair-forming layers, supported by fluid-dynamic modelling. Experiments showed that even when cell division was blocked, hair fibres continued to grow—unless actin activity in the ORS was inhibited. This suggests mechanical pulling is a key driver of human hair fibre extrusion.

A new case series adds to growing evidence that tofacitinib—a JAK inhibitor already used for arthritis—can help treat severe alopecia areata. Five long-term, treatment-resistant patients received the drug; three showed strong hair regrowth, echoing wider research involving nearly 200 patients, where most achieved over 50% improvement. Side effects were generally mild, with no serious complications reported. While results were weaker in patients with alopecia totalis/universalis, the study supports tofacitinib as a cost-effective option when newer AA drugs are unavailable. Larger UK-based studies are still needed to confirm long-term safety.

A new study suggests that cell-free RNA in blood could help diagnose and predict the severity of female pattern hair loss. Researchers analysed plasma samples from 65 women with FAGA and found distinct gene expression patterns linked to disease progression, particularly reduced levels of DNAJB9, a gene involved in cellular stress responses and androgen receptor regulation. Using machine learning, the team built a predictive model that successfully distinguished between healthy controls and different severities of FAGA. Although early-stage, the findings point to promising blood-based biomarkers that could improve future diagnosis and personalised treatment.

A new analysis of breast cancer patients in scalp-cooling trials found that 12% still experienced persistent chemotherapy-induced alopecia six months after treatment. Tamoxifen monotherapy was the strongest predictor of ongoing hair loss, significantly reducing hair-thickness recovery compared with no endocrine therapy. Genetic variants linked to alopecia showed only weak, non-significant associations. The study highlights that even with scalp cooling—widely used in UK cancer centres—some patients remain at risk of long-term thinning. Researchers stress the need for personalised counselling and closer dermatology support, particularly for women starting tamoxifen.

Chinese researchers have developed an AI-powered system that grades male pattern baldness with over 96% accuracy, outperforming traditional scales like the Norwood-Hamilton classification. Using advanced image segmentation, the model measures the ratio of hair loss area to healthy scalp, offering a more objective and consistent method for assessing severity. This could lead to faster, data-driven diagnoses and more tailored treatment plans. While further validation and broader datasets are needed, the approach marks a major step toward standardising hair loss evaluation in clinical settings.

A new genetic study from Chinese researchers explored whether poor sleep might cause hair loss—or vice versa. Using data from large UK and Finnish databases, the team examined links between sleep traits (like insomnia, short sleep, or being a “morning person”) and different alopecia types. Results suggested that insomnia may increase the risk of alopecia areata, while hair loss itself could slightly reduce sleep duration or shift body clock patterns. However, none of the findings remained statistically strong after corrections, meaning more research is needed before firm conclusions can be drawn.

A large German study involving over 500 patients found that both scarring and non-scarring alopecia significantly reduce quality of life, especially affecting mental wellbeing. Non-scarring hair loss, such as alopecia areata, was linked to higher anxiety and depression than scarring forms. Younger people and women—particularly those with non-scarring alopecia—reported greater emotional distress and social difficulties. Researchers recommend that psychological support should be integrated into hair loss management, as the emotional burden often extends beyond cosmetic concerns.

New research published in Science Advances reveals that alopecia areata (AA) — an autoimmune cause of hair loss — is driven not just by CD8 “killer” T cells, but also by CD4 “helper” T cells. These CD4 cells adopt a TH1 effector state and trigger hair loss through the release of interferon-gamma (IFN-γ), which in turn activates CD8 T cells and breaks down the hair follicle’s immune privilege. Crucially, blocking IFN-γ from CD4 cells halted disease development in mice, suggesting new therapeutic avenues beyond current JAK inhibitors.

A Korean survey of nearly 700 people with hair loss found that while telemedicine is widely available, only 31% have used it for treatment. Most cited doubts about remote diagnosis accuracy, though over 80% would consider it in future for its convenience and lower cost. Finasteride and dutasteride were the most common treatments among users. The study suggests that a hybrid care model—combining initial in-person diagnosis with virtual follow-ups—could overcome trust barriers and align with growing global digital health trends.

A new systematic review from Stellenbosch University and the University of Turin examined whether minoxidil—taken orally or applied topically—can help treat traction alopecia (TA), a hair loss condition often caused by tight hairstyles. Across six small studies, some hair regrowth was observed from three months onwards. However, the evidence remains weak due to limited data and high bias risk. Experts stress that behavioural changes to reduce scalp tension should remain the first-line treatment, with minoxidil considered only as a supportive option following shared decision-making.

A new study reveals that fat cells beneath the skin play a key role in triggering hair regrowth after injury. When the skin is damaged, immune cells (macrophages) stimulate nearby adipocytes to break down stored fat, releasing monounsaturated fatty acids (MUFAs). These MUFAs awaken dormant hair follicle stem cells by boosting their energy production and mitochondrial function through the Pgc1-α pathway. Crucially, applying MUFAs topically also promoted hair growth in mice, suggesting a potential new, metabolism-based treatment for hair loss.

UK researchers have developed resveratrol-loaded nanostructured lipid carriers (NLCs) designed to work with scalp cooling therapy to prevent chemotherapy-induced hair loss. The antioxidant resveratrol, encapsulated within these stable nanoparticles, effectively targets hair follicles, reducing oxidative stress caused by chemotherapy drugs. Early tests showed that the formulation reaches the follicular reservoir within six hours, potentially enhancing scalp cooling results. This combined treatment could significantly reduce hair loss and improve quality of life for cancer patients undergoing chemotherapy.

Researchers in China have demonstrated that treatments derived from human amniotic mesenchymal stem cells (hAMSCs) — specifically their conditioned medium and lysate — can significantly boost hair regrowth in mice with androgenetic alopecia (pattern baldness). These treatments improved blood vessel formation, encouraged dermal papilla cell growth, and reduced inflammation, all of which supported stronger hair regeneration. The study suggests that hAMSC-based therapies could become a promising, non-hormonal alternative to minoxidil for treating male and female pattern hair loss.

A small Japanese trial has found that a new stem cell-based treatment using patients’ own blood cells could safely improve hair growth in men with androgenic alopecia. Five participants received injections of cultured mononuclear cells (MNC-QQ), with all showing thicker, denser hair and no side effects after six months. The findings suggest this regenerative approach could become a promising alternative to current hair loss treatments like finasteride or minoxidil.

A year-long Chinese study tracked 400 people with alopecia areata (AA) to understand how the condition progresses and responds to treatment. Over half the participants showed significant hair regrowth within six months, but nearly a third relapsed by the end of the year—often those with a history of previous flare-ups. Younger patients and those with active, short-term disease responded best. The research also linked reduced itching and pain to visible recovery, highlighting the emotional and physical toll of AA.

A new Bayesian meta-analysis comparing leading JAK inhibitors for severe alopecia areata reveals that deuruxolitinib (8mg BID) delivers the strongest short-term hair regrowth results, outperforming baricitinib and showing favourable outcomes over ritlecitinib. Drawing on data from over 4,500 participants, the study found deuruxolitinib most effective on the Severity of Alopecia Tool (SALT) scales. While promising, researchers caution that more head-to-head trials are needed to confirm its superiority and ensure long-term safety for UK patients seeking advanced treatment options.

Recent research highlights liposomal drug delivery systems as a breakthrough in treating androgenetic alopecia (pattern hair loss). These microscopic, lipid-based carriers enhance the penetration and precision of treatments like minoxidil and finasteride directly into hair follicles — the root site of the condition. By improving drug stability and minimising side effects, liposomes could transform topical therapy for both men and women. However, challenges such as manufacturing consistency and long-term stability still need addressing before these innovations reach mainstream clinical use.

A new Italian study has found that adding the dietary supplement AGA-P to standard hair loss treatments like minoxidil and finasteride significantly boosts results for both men and postmenopausal women with androgenetic alopecia. The supplement — containing zinc, vitamin C, L-cystine, pumpkin seed extract, and saw palmetto — improved hair growth scores and patient satisfaction without notable side effects. Researchers say these findings support combining nutritional support with medication to enhance regrowth and treatment response, though larger, longer-term trials are needed to confirm results.

A new AI-powered tool is set to revolutionise how clinicians assess alopecia areata. By automatically calculating an “AI-SALT” score, it delivers more accurate, sensitive, and objective results than traditional manual assessments. In a recent case, the technology detected early signs of hair regrowth that standard methods missed—helping keep the patient motivated to continue treatment. The system could also streamline insurance approvals by providing verifiable data. Though still in early testing, this AI approach shows promise for improving both diagnosis and treatment outcomes in hair loss care.

A recent case report highlights two adults with severe, treatment-resistant alopecia areata who achieved full hair regrowth using baricitinib, an oral JAK1/JAK2 inhibitor. Both patients showed visible improvement within three months and complete recovery within 9–12 months, with minimal side effects such as mild headaches and temporary cholesterol increases. The findings support baricitinib’s growing reputation as a safe and effective option for stubborn alopecia cases, offering hope for those who fail to respond to steroids or immunosuppressants. Continued monitoring and longer-term studies remain essential to confirm sustained benefits.

A new study from Korean researchers used advanced 3D Raman spectroscopy to measure how well hair absorbs and retains moisture and nutrients from products. Comparing untreated, water-treated, and product-treated hair, the findings showed that the “Minoxell Scalp Intensive Ampoule” achieved deeper penetration, greater moisture retention, and less dryness than water or no treatment. This pioneering imaging method allows scientists to visualise how hair care formulas actually work inside each strand — setting a new benchmark for testing product efficacy and supporting better treatments for hair loss and dryness.

A new analytical review warns that finasteride, commonly prescribed for male hair loss, may significantly increase the risk of depression and suicide — even after stopping the drug. Despite early evidence dating back to 2002, regulators and manufacturers failed to act for over two decades, potentially leaving hundreds of thousands affected. The study highlights serious gaps in pharmacovigilance, with underreporting, redacted FDA data, and a lack of postmarketing studies by drug makers. The author urges regulators to suspend finasteride’s cosmetic use until safety is proven and demands greater transparency in drug safety monitoring.

A new Japanese case series has explored the use of finasteride to treat androgenetic alopecia (male-pattern baldness) in transgender men undergoing testosterone therapy. Three participants received low-dose finasteride for six months, showing clear improvements in hair growth without major side effects. However, two patients experienced a return of menstruation, raising concerns that the drug may partially counteract masculinising effects of hormone therapy. While the findings suggest finasteride could be safe and effective for transgender men, further large-scale trials are needed to confirm its role alongside other hair loss treatments like minoxidil.

A newly published case report documents the first known instance of plica neuropathica (also called plica polonica) occurring alongside diffuse alopecia. The condition causes irreversible matting of hair into a hard, tangled mass, often linked to poor hygiene, friction, or certain shampoos. In this case, a 62-year-old woman developed both diffuse hair loss and plica polonica after illness, nutritional deficiencies, and medication use. Diagnosis confirmed androgenetic alopecia with acute telogen effluvium, and treatment with topical minoxidil began. The report stresses the importance of recognising unusual complications like plica neuropathica when assessing unexplained hair loss.

A major global study has confirmed that women are nearly twice as likely as men to develop alopecia areata (AA) over their lifetime. Between 1990 and 2021, the risk rose to 32% for women and 17% for men, with projections suggesting this will climb to 34% and 19% respectively by 2050. Women face a longer period of risk (ages 20–50 versus men’s 20–30) and are particularly affected in wealthier nations. The findings highlight the need for sex-specific approaches to prevention, diagnosis, and treatment of AA.

A new study highlights 2,3,5,4′-Tetrahydroxystilbene-2-O-β-D-Glucoside (TSG), the active compound in the traditional Chinese herb Polygonum multiflorum, as a potent promoter of hair regeneration. Using mouse models and 3D skin cultures, researchers found TSG accelerates hair follicle growth by stimulating Th22 immune cells, which secrete IL-22 to drive follicle proliferation and differentiation. Compared to other compounds, TSG showed the strongest effect, suggesting it could offer a safer alternative to conventional treatments like minoxidil and finasteride, which often carry side effects. This work opens new avenues for immune-based hair loss therapies.

Researchers have built the first machine-learning tool to predict how quickly lichen planopilaris (LPP) – a scarring hair loss disorder – will progress. Analysing 312 patients, the model achieved 92% accuracy and flagged three key, modifiable risks: delayed diagnosis, vitamin D deficiency and severe trichoscopic findings. By identifying high-risk cases earlier, clinicians could intervene sooner, preserve hair follicles and reduce NHS costs linked to late treatment. A UK-style web calculator and multicentre trial are planned, potentially shifting LPP management from reactive care to personalised prevention.

This review highlights the potential of combining multifunctional plant extracts with cutting-edge nanotechnology to improve treatment for androgenetic alopecia (AGA). While UK patients often rely on minoxidil and finasteride, these options have limited effectiveness and side effects. Plant-based compounds, such as saw palmetto, can target multiple pathways like androgen activity and inflammation. Advanced nanocarriers – including liposomes and microemulsions – promise better scalp penetration, stability, and patient compliance. However, large-scale trials, regulatory clarity, and manufacturing consistency are still needed before these innovations can transform AGA care for British men and women.

A US survey of 26 dermatology residents and attendings explored real-world management of central centrifugal cicatricial alopecia (CCCA), a scarring hair loss condition mainly affecting Black women. Most clinicians used topical and intralesional corticosteroids first-line to control inflammation, with topical minoxidil also widely prescribed – often ahead of guideline recommendations. Oral tetracyclines, oral minoxidil and compounded topicals were used less frequently, while procedural options like PRP and LED light therapy were absent. Many residents felt less confident treating CCCA than attendings. The findings highlight gaps in training, limited access to therapies, and the urgent need for UK-relevant clinical guidelines.

A systematic review of 97 global cases highlights that paradoxical psoriatic alopecia – hair loss caused by biologic medicines meant to treat inflammatory diseases – mainly affects younger women. Most cases were linked to TNF-alpha inhibitors such as adalimumab and infliximab, frequently prescribed for Crohn’s and other autoimmune conditions. Distinctive scalp changes (including sebaceous gland shrinkage and a mixed inflammatory cell infiltrate) help differentiate it from ordinary psoriasis-related hair loss. Encouragingly, nearly 90% of patients saw at least partial regrowth, especially after stopping or switching drugs, though a small minority had ongoing or permanent hair loss.

A new study published in PLOS ONE links disrupted cholesterol production with the loss of hair follicle stem cell function, especially in primary cicatricial alopecia (PCA). By analysing scalp samples and conducting lab experiments on human hair follicle cells, mice, and organoid cultures, researchers found that blocking cholesterol synthesis or accumulating sterol intermediates damages stem cells and prevents hair regrowth. This highlights cholesterol’s crucial role in maintaining healthy hair follicles and offers fresh insight into why conditions like PCA lead to irreversible hair loss.

Biotin, widely marketed for hair and nail regrowth, lacks strong clinical evidence beyond true vitamin B7 deficiency. This cautionary paper warns that high-dose biotin can distort key blood tests used in cancer care—potentially delaying treatment decisions or masking recurrence—while offering little proven benefit. Only 6% of cancer patients reportedly discuss hair regrowth options with their oncologist, yet safer alternatives like topical minoxidil show stronger results post-chemotherapy. UK oncologists are urged to ask about supplement use, advise a biotin “washout” before tests, and guide patients toward evidence-based options.

A new systematic review highlights a potential link between popular weight-loss and diabetes drugs such as semaglutide and tirzepatide and hair loss. Drawing on five studies with nearly 3,000 adults, the review found mixed results: some patients experienced alopecia, while others reported hair regrowth, especially with tirzepatide. Rapid weight loss, nutrient deficiencies and hormonal shifts may explain the effect. With GLP-1 use rising sharply in the UK, the authors call for better reporting, patient counselling and larger studies to understand these under-recognised side effects.

A small head-to-head trial of 40 adults with localised alopecia areata found that monthly intralesional triamcinolone injections produced far better hair regrowth and patient satisfaction than methotrexate over six months. SALT scores (measuring hair loss) dropped by over 50% with triamcinolone but worsened in the methotrexate group. Side-effects were mild in both arms. UK clinicians may still consider methotrexate for steroid-intolerant patients, but the data support triamcinolone as the more reliable first-line option. Larger multicentre studies are needed.

A systematic review of 11 clinical studies (298 patients) found that exosome therapy – particularly mesenchymal stem cell (MSC)-derived exosomes from adipose tissue, placenta, foreskin, hair follicles, bone marrow, and umbilical cord – consistently improved hair density and thickness in androgenetic alopecia (male/female pattern baldness) and even rare conditions like chemotherapy-induced alopecia. Two randomised controlled trials provided the strongest evidence, showing up to 35 extra hairs/cm² and thicker hair shafts with high patient satisfaction. Across all studies, side effects were mild (temporary redness or itching) with no serious complications reported. However, small sample sizes and differing protocols mean larger UK-based trials are needed before clinical roll-out.

Alopecia areata (AA), a leading autoimmune cause of non-scarring hair loss, is strongly linked to immune cell recruitment around hair follicles. This meta-analysis of 46 studies shows that Th1 chemokines (CXCL9, CXCL10, CCL5) are consistently elevated, driving follicle attack, while Th2 chemokines (CCL13, CCL17, CCL22) also play a key role—particularly in patients with atopy. Elevated CXCL8, CCL20, and other signals reveal broader immune involvement. Findings suggest AA is not just a Th1-driven disease but a complex immune disorder, pointing to future treatments combining wider immunomodulation with personalised approaches.

Concerns about blood clot risks from JAK inhibitors have been eased by new research into baricitinib for alopecia areata. In a six-month study of 47 patients, no thromboembolic events occurred and laboratory markers even showed a reduction in clotting risk. With baricitinib already offering proven regrowth results, this study provides reassurance for patients and clinicians considering the treatment. While longer-term monitoring is needed, experts say routine clotting tests are unnecessary unless patients have known risk factors.

A new study has confirmed scalp micropigmentation (SMP) as a safe, effective option for camouflaging hair loss. Ten patients with either male-pattern baldness or scarring alopecia underwent a refined three-session SMP technique, achieving strong cosmetic improvements and high satisfaction rates. Results were most durable in androgenetic alopecia, while fading was greater in scarring cases. Importantly, no adverse effects were reported, making SMP a reliable, minimally invasive solution for those seeking immediate cosmetic results.

A new case series has found that the JAK1 inhibitor upadacitinib may be a safe and effective treatment for adolescents with severe alopecia areata (AA), even in those without other immune conditions. Three teenagers given 15mg daily showed significant hair regrowth within months, with eyebrow and pubic hair appearing first and scalp hair following by month four. A wider literature review covering 26 young patients worldwide also confirmed positive outcomes, with only mild side effects such as acne. Researchers stress the need for larger, longer trials, but results point to a promising new option for teenage AA.

A new study has found that exosomes derived from platelet-rich plasma (PRP-exos) could offer a breakthrough in hair loss treatment. In lab and mouse models, PRP-exos boosted the growth and survival of hair follicle stem cells, reduced oxidative stress, and encouraged new hair follicle development. Researchers discovered that PRP-exos work by activating the SIRT1/FoxO3a pathway, which protects cells from damage and promotes regeneration. With current hair loss treatments offering limited results and side effects, PRP-exos may emerge as a promising new option for conditions like androgenetic alopecia and alopecia areata.

A global Phase 3 trial is testing upadacitinib, an oral JAK inhibitor, for severe alopecia areata in both adolescents and adults. The study will enrol around 1,500 participants across nearly 280 sites worldwide, with treatment lasting up to 160 weeks. Patients will receive either upadacitinib or placebo, with opportunities to switch treatment arms depending on their progress. Regular monitoring will assess safety, side effects, and regrowth. Results could provide a major step forward in expanding treatment options for those with extensive alopecia areata.

A new review highlights how low-level light therapy (LLLT) is emerging as a promising, non-invasive option for different types of hair loss. Evidence shows it can improve hair density in androgenetic alopecia, reduce shedding in telogen effluvium, and even help modulate immune responses in alopecia areata. Early case reports also suggest benefits in scarring conditions such as lichen planopilaris and CCCA. While home-use devices are expanding access, standardised protocols and long-term studies are still needed.

An Italian clinical trial has found that AGA-P, a dietary supplement containing saw palmetto, pumpkin seed extract, L-Cystine, and vitamin C, improves results when combined with minoxidil or finasteride for androgenetic alopecia (male and female). After six months, 36.5% of patients taking the supplement alongside medication saw major improvements, compared with 25% on medication alone. The supplement was well tolerated, suggesting it could become a useful add-on for hair loss treatment.

New research reveals clonally expanded CD8+ T cells play a direct role in triggering and sustaining alopecia areata (AA). These immune cells not only kill hair follicle cells but also drive inflammation, fuelling relapse even after treatment with JAK inhibitors. The findings suggest that tracking T-cell clones could help predict disease progression and response to therapy, while future treatments may target these pathogenic cells to reduce recurrenc

New bioinformatics research suggests COVID-19 can provoke alopecia areata (AA) through overlapping immune system disruptions. Analysis of shared genetic markers revealed that both conditions involve heightened chemokine and cytokine signalling. Crucially, existing drugs targeting these immune pathways—such as Alemtuzumab and Bertilimumab—may hold promise for treatment. These findings could shape future therapies for patients in the UK with post-COVID hair loss or treatment-resistant AA.

Doctors have reported the world’s first case of basal cell carcinoma (BCC) arising within congenital triangular alopecia (CTA), a rare childhood-onset hair loss condition. A 48-year-old woman developed BCC in a long-standing bald patch on her temple, suggesting that the absence of protective hair may increase vulnerability to UV damage. UK dermatologists are urged to monitor stable alopecic patches closely, as even benign-appearing bald spots could conceal malignancy.

A large Israeli study of over 33,000 patients with alopecia areata (AA) has confirmed a significant association with autoimmune thyroid diseases (AITD), including Hashimoto’s and Graves’. Those with AA were around 1.7 times more likely to have thyroid conditions than healthy controls. While further research is needed to decide if routine thyroid screening is warranted, the findings strengthen evidence of shared autoimmune mechanisms. This is especially relevant for UK clinicians managing patients with AA, particularly younger individuals.

New research on Arabidopsis thaliana shows that the protein S-acyl transferase PAT4 plays a key role in root hair growth, not only in length but also in angle and shape. Loss of PAT4 function led to swollen, branched, or upturned root hairs with reduced growth angle, limiting soil contact. Overexpression altered growth angle too, while auxin treatments worsened defects in mutants. Interestingly, related protein PAT16 was found not to influence root hair growth. This study highlights root hair growth angle as a fresh measure for understanding plant nutrient uptake efficiency.

A review of nine studies suggests alopecia could be an under-recognised side effect of GLP-1 receptor agonists such as semaglutide, tirzepatide and liraglutide, increasingly prescribed for weight loss in the UK. Reports to US regulators exceed 1,000 cases, with patterns like telogen effluvium and androgenetic alopecia noted. While causality is unconfirmed, rapid weight loss and drug effects on hair cycles may play a role. Awareness may help clinicians balance benefits against quality-of-life concerns and avoid unnecessary investigations.

A review of 21 studies found frequent misdiagnosis of scalp and hair disorders in patients with skin of colour, sometimes missing serious conditions like lymphoma or neurosyphilis. Over 60% of cases involved incorrect initial diagnoses, often mistaking alopecia areata or lichen planopilaris for central centrifugal cicatricial alopecia. Scalp biopsies proved more reliable than trichoscopy for accuracy. The findings underline the need for better training and representation in dermatology to improve outcomes for UK patients from diverse backgrounds.

Researchers have developed finasteride-loaded microspheres that release the drug in two phases — a rapid burst over four days to quickly suppress dihydrotestosterone (DHT), followed by a steady release for 28 days. In animal models, this approach both reduced early DHT levels and sustained suppression, promoting faster regrowth than daily tablets. If proven in humans, this could mean fewer doses, quicker results, and better treatment adherence for androgenetic alopecia sufferers.

A comprehensive review highlights adipose-derived stem cells (ADSCs) and their derivatives as promising treatments for hair loss, thanks to their ability to stimulate follicles, reduce inflammation, improve blood supply, and combat oxidative stress. Clinical trials show benefits in androgenetic alopecia and alopecia areata, especially with conditioned media, stromal vascular fractions, and exosomes. UK researchers are urged to explore standardised dosing, delivery methods, and combination therapies to move ADSCs from lab to clinic.

Researchers developed high-hardness, fast-dissolving microneedles loaded with platelet-rich plasma (PRP) using a machine-learning-optimised material mix. In mice with androgenetic alopecia, these microneedles outperformed minoxidil, promoting hair regrowth via the Wnt/β-catenin pathway while delivering sustained growth factors and antibacterial protection. This pain-free, synthetic-free delivery method could offer UK patients a safer, more effective alternative to injections for AGA.

A Chinese study tracked 67 obese patients post-bariatric surgery, finding major shifts in amino acid levels. Leucine in particular emerged as an independent risk factor for moderate-to-severe hair loss three months after surgery. These results suggest nutritional imbalances, especially involving certain amino acids, could trigger post-operative alopecia. For UK clinicians, monitoring amino acid profiles may help identify and support at-risk patients after weight-loss surgery.

A major new meta-analysis has revealed that patients suffering from Primary Cicatricial Alopecia (PCA) — a form of scarring hair loss — face significantly higher risks of various health conditions compared to the general population. Drawing on data from over 33,000 patients, the study highlights links between PCA and serious comorbidities such as systemic lupus erythematosus, hypothyroidism, diabetes, coronary artery disease, and skin cancers. Particularly notable is the high prevalence of hypothyroidism (up to 19%) and allergic contact dermatitis (up to 41%) in PCA subtypes. UK dermatologists and GPs are urged to screen PCA patients more broadly for systemic illnesses and psychological conditions like anxiety, especially in women.

A new formulation of topical finasteride could revolutionise hair loss treatment by offering strong results without the side effects of oral pills. Developed using HPCD-enhanced chitosan nanocapsules, this cutting-edge delivery system improves drug solubility, skin penetration, and safety. In lab and animal studies, it outperformed existing topical products—even with a lower dose—while avoiding systemic side effects like sexual dysfunction. For men wary of oral finasteride, this could be a safer and equally effective alternative in the fight against male pattern baldness.

Alopecia caused by cosmetic injection procedures—though rare—is becoming more frequently reported. This comprehensive review of 25 studies covering 48 patients reveals that dermal fillers and similar injections can lead to localised hair loss, often linked to vascular complications. Symptoms can appear days to weeks after treatment and may be accompanied by skin discolouration or necrosis. The study urges cosmetic practitioners to be more aware of this underreported risk and to have preventive and responsive protocols in place.

A new phase II study suggests that topical dutasteride (0.05%) outperforms oral finasteride in treating male pattern hair loss, or androgenetic alopecia (AGA). Applied daily for 24 weeks, the topical solution significantly increased both hair count and hair thickness, with greater patient satisfaction and fewer systemic hormonal changes. Importantly, no major side effects or skin irritation were reported, unlike oral finasteride, which is linked to sexual side effects in some men. These findings could reshape the treatment landscape for UK men seeking safer, more effective hair regrowth therapies.

In a promising step for those affected by severe alopecia areata, AbbVie’s phase 3 clinical trial has shown that upadacitinib (Rinvoq) significantly improves scalp hair regrowth. At week 24, over half of patients taking 30 mg achieved at least 80% scalp coverage, compared to just 3.4% on placebo. Improvements also extended to eyebrow and eyelash regrowth, with a strong safety profile and low dropout rate. As the first pivotal programme to meet complete hair regrowth standards (SALT = 0), these findings could bring real hope to UK patients seeking effective AA treatments.

A large Chinese study found that patients with alopecia areata generally lack key knowledge about their condition, despite showing positive attitudes and engaging in treatment efforts. Over 70% were unclear on basic facts, like stress-related triggers and treatment options. Anxiety and income levels also affected how actively patients managed their condition. The findings point to an urgent need for better education, clearer communication, and integrated mental health support—lessons that apply globally, including in the UK.

The FDA has granted Fast Track designation to rezpegaldesleukin, a novel biologic therapy targeting severe-to-very severe alopecia areata. The drug boosts the body’s regulatory T cells to help reset immune balance, tackling the root cause of the disease rather than just symptoms. With Phase 2b results expected in December 2025, this injectable treatment could become a game-changer for adults and teens alike. The designation means faster regulatory review, potentially speeding up its availability for patients.

Chinese biotech firm ImmVira has secured INCI approval for EX104, the world’s first engineered exosome designed to treat alopecia through non-invasive topical application. This milestone paves the way for a new era in anti-ageing and hair restoration products that work at the cellular level—without surgery or pills. With the UK’s booming cosmetic market and demand for advanced home-use treatments, this innovation could soon redefine hair care routine

A network meta-analysis reviewing 12 studies and nearly 4,000 patients has confirmed that oral JAK inhibitors are generally safe for treating alopecia areata. However, some types—especially baricitinib and deuruxolitinib—were linked to side effects such as acne, urinary infections, and raised muscle enzyme levels. The risks appear to increase with dosage. For Brits considering these new treatments, the benefits are promising, but potential side effects need monitoring.

A Chinese study on mice with alopecia areata found that microneedling not only stimulated hair regrowth but also helped rebalance gut bacteria and reduce certain inflammatory compounds. Mice treated with microneedling showed restored microbial diversity and changes in key short-chain fatty acids, which may play a role in hair health. These findings suggest that microneedling could offer dual benefits—boosting scalp and gut health—and opens a new avenue for holistic alopecia treatments.

Chinese researchers have developed a dual-action microneedle patch to tackle male pattern baldness (AGA) by combining dutasteride-loaded glycyrrhizin micelles and ROS-scavenging nanoparticles. This innovative patch inhibits 5α-reductase (reducing DHT levels) and eliminates harmful oxidative stress at the follicle site, effectively boosting hair regeneration in both lab and animal tests. Unlike oral medications, this approach avoids systemic side effects and directly delivers treatment to the scalp—offering a potentially safer, more efficient future solution for hair loss.

A recent pooled analysis from the phase 3 THRIVE-AA1 and THRIVE-AA2 trials shows that deuruxolitinib (8 mg twice daily) significantly boosts hair satisfaction among patients with severe alopecia areata. By week 24, 95.7% of responders reported being satisfied or very satisfied with their hair, compared to none in the placebo group. The oral JAK1/2 inhibitor helped one-third of participants reach the key hair regrowth threshold (SALT ≤20), offering hope for a disease that heavily impacts mental well-being.

A new meta-analysis reveals a potential link between alopecia areata (AA) and increased cardiovascular disease (CVD) risk, particularly in patients with more severe forms such as alopecia totalis and universalis. Drawing on data from over 238,000 AA patients across three countries, researchers found that those with extensive hair loss had a significantly higher chance of developing CVD. However, no notable association was found in patients with patchy AA or for specific conditions like stroke or heart attack. The findings highlight the need for greater cardiovascular monitoring in AA patients, especially those with severe cases.

A novel microneedle delivery system using chitosan-stabilised finasteride nanocrystals (CS-FIN-NCs) has shown promise in treating AGA without the systemic side effects of oral finasteride. The microneedles deliver the drug directly to hair follicles, boosting local accumulation and encouraging hair regrowth in animal models by inhibiting DHT and enhancing follicular angiogenesis. This dual-action system addresses both hormonal imbalance and follicle health, potentially offering UK patients a safer, targeted alternative to oral medications.

Groundbreaking research using single-cell sequencing and spatial transcriptomics has decoded the biological chaos behind lichen planopilaris (LPP), a scarring type of alopecia. UK readers affected by unexplained patchy baldness may be surprised to learn that immune cells—especially CD8⁺ memory T-cells and macrophages—attack hair follicles directly. This triggers interferon-related inflammation, stem cell damage, and irreversible scarring. Two molecules, IFN-γ and oncostatin M, were found to play key roles. These findings pave the way for targeted treatments like JAK inhibitors.

An AI-powered analysis of data from over 1 million MDhair app users has revealed fresh insights into hair loss patterns. Androgenetic alopecia remains the most common cause, especially in men, but women report hair thinning earlier. Key risk factors include age, genetics, menopause, PCOS, thyroid issues, stress, and COVID-19. Contrary to popular belief, diet and shampoo habits show little impact. Post-COVID hair loss was significantly higher, indicating telogen effluvium. These findings could help personalise treatment approaches and identify at-risk groups earlier.

A major UK study from King’s College London reveals that stigma and shame around alopecia cause greater psychological distress than hair loss itself. Surveying 596 adults with alopecia areata, researchers found over half felt self-conscious or ashamed, and a third said it impacted daily life. Positive perceptions of the condition were linked to reduced anxiety, underlining the urgent need for integrated mental health support in alopecia care. Experts call for early psychological intervention and improved awareness among clinicians to tackle what is too often dismissed as a “cosmetic issue.”

A new review explores which hair loss treatments are safe for breastfeeding mothers – a vital yet under-discussed issue. While minoxidil and PRP appear low-risk, drugs like methotrexate, isotretinoin, and JAK inhibitors such as tofacitinib should be avoided. Natural remedies like rosemary oil lack data, and retinoids are flagged as unsafe. Encouragingly, options like spironolactone, vitamin D, and low-level laser therapy remain promising. With many UK women balancing hair loss treatment and breastfeeding, this guide offers much-needed clarity for safer choices.

A 29-year-old man presented with patchy hair loss and itchy scalp lesions – but the real cause wasn’t stress or fungus. It was secondary syphilis. This rare form of hair loss, called syphilitic alopecia, often mimics conditions like alopecia areata and is easy to misdiagnose. In this case, early detection and penicillin treatment led to full hair regrowth within three months. The report urges UK clinicians to consider STIs, particularly syphilis, when faced with unexplained hair loss in sexually active patients – especially given rising STI rates across the UK.

Pharma giant Sun Pharma has launched LEQSELVI™ (deuruxolitinib) in the United States, a JAK1/2 inhibitor targeting severe alopecia areata. In clinical trials, nearly a third of patients experienced near-full hair regrowth in just 24 weeks. With fast results and oral dosing, LEQSELVI brings new hope to those living with this distressing autoimmune condition. However, the drug carries serious safety warnings, including risks of infections, malignancies, and cardiovascular events. It’s not yet approved in the UK, but if authorised, it could offer a lifeline to British patients seeking rapid and effective results in managing alopecia areata.

A comprehensive review of 26 clinical studies has found that exosome therapy may outperform both PRP and minoxidil in treating androgenetic alopecia (AGA). Derived from stem cells, exosomes deliver regenerative molecules that improve hair density and thickness with minimal side effects and fewer sessions. While PRP remains a strong and well-established option, it often requires repeated injections and results vary by patient. Minoxidil, though widely accessible, shows the least durable results and must be used continuously. Despite the promise of exosomes, their long-term effects remain under-researched, and high costs and lack of standardisation still limit widespread use.

A large US study has shown that people—especially adolescents—with severe alopecia areata (AA) are at significantly higher risk of developing atopic dermatitis (AD). The immune system appears to play a central role, with overlapping pathways between the two conditions. Dermatologist involvement and early screening are key, and dual-target treatments like JAK inhibitors may offer a future-proof solution. For British clinicians and patients, this highlights the importance of viewing AA not in isolation, but as part of a broader immunological picture requiring integrated care.

Male pattern baldness (mpAGA) is often viewed as an age-related nuisance, but new research reframes it as a physiological process involving the miniaturisation of hair follicles in genetically predisposed men. This review highlights the biological complexity of mpAGA, questioning long-held beliefs about the role of androgens. Instead, it explores alternative factors such as oxidative stress, immune cells, and even the scalp’s microbiome. The authors call for new therapies beyond hormone-focused treatments and propose that mpAGA may be a useful model for understanding organ remodelling and ageing.

Groundbreaking Japanese research has revealed that serotonin (5-HT) — a chemical best known for regulating mood — may also significantly stimulate hair growth. The study found that serotonin activates dermal papilla (DP) cells, which are crucial for hair follicle development, leading to increased hair shaft elongation. Using human hair follicle organ cultures and organoids, scientists observed similar growth-boosting effects from sumatriptan, a migraine medication that activates serotonin receptors. The findings pave the way for serotonin-based therapies for alopecia, though high doses raise safety concerns. For the UK’s hair loss community, this opens new doors for gut-brain-hair research and innovative treatment options.

A major meta-analysis involving over 460,000 alopecia areata (AA) patients reveals a strong association between AA and a range of immune-mediated conditions, including thyroid issues, inflammatory bowel disease, asthma, and atopic dermatitis. Particularly notable is the 2.75x higher risk of coeliac disease and a 6x increased likelihood of vitiligo among AA sufferers. While study limitations exist, these findings highlight the urgent need for holistic screening and care in people with AA. For UK patients, especially those with autoimmune conditions, early detection could be key to managing long-term health risks.

A new international study has highlighted the strong connection between alopecia areata (AA) and mental health issues—particularly anxiety and depression—among females, with the most pronounced links found in China, India, Brazil, and Japan. The data, sourced from the Global Burden of Disease Study 2021, revealed that women under 20 are especially vulnerable. Interestingly, no significant correlations were found in males. Experts stress that mental health support should be an essential part of AA treatment, as the psychological toll of hair loss can be as impactful as the physical symptoms.

Tofacitinib, a JAK inhibitor used to treat alopecia areata, can be highly effective—but not without complications. This case study follows a 26-year-old patient who initially responded well to the drug but experienced relapse, requiring corticosteroids and ultimately a switch to Ritlecitinib. The article highlights the need for personalised, adaptive treatment strategies and suggests that targeting the JAK-STAT pathway alone may be insufficient. For UK patients exploring JAK inhibitors, this report reinforces the importance of close clinical monitoring and considering combination or alternative therapies if results plateau.

Alopecia areata (AA) has been linked to heightened levels of anxiety and depression, particularly in young women, according to data from the Global Burden of Disease Study 2021. The study reviewed mental health correlations across multiple countries and found the strongest links in China, India, Japan, and Brazil. Results show a clear emotional toll associated with AA, especially among females under 55, reinforcing the need for psychological support in treatment plans. These insights underscore the importance of recognising the broader psychological burden AA places on patients—not just the visible symptoms.

A new study published in Stem Cell Research & Therapy highlights how hair loss, affecting millions globally, is driven by diverse causes such as stress, hormones, and nutritional deficiencies. It introduces a game-changing alternative: hair follicle organoids developed from induced pluripotent stem cells (iPSCs). These lab-grown follicles could solve current limitations, offering personalised, vascularised, and scalable grafts. With robust preclinical evidence and ongoing technological advances, iPSCs signal a breakthrough era in tackling hair loss – one that’s not just cosmetic, but deeply restorative.

A new treatment for androgenetic alopecia (AGA) combines microneedles made of biodegradable hydrogel with iridium nanoparticles and fibroblast growth factor (bFGF). This dual-action approach tackles two root causes of hair loss: oxidative stress and poor blood supply. In mice, it outperformed minoxidil by reducing inflammation, boosting blood flow to hair follicles, and promoting thicker hair regrowth with fewer applications. The microneedles also stimulate the scalp mechanically, enhancing their effects. The promising results offer a safer, more efficient alternative to current AGA treatments.

In a UK-led phase II trial, a novel dithranol cream with nanoparticle delivery achieved a 76% response rate in mild-to-moderate alopecia areata, significantly outperforming placebo. While skin irritation was common early on, it was mostly mild and diminished over time. The 1% concentration yielded the best balance of effectiveness and tolerability. This repurposed therapy, long used in psoriasis, may offer a low-cost topical option for early-stage AA.

A meta-analysis of three randomised trials comparing single- versus double-spin platelet-rich plasma (PRP) in androgenic alopecia (AGA) found minimal but consistent improvements with single-spin methods. Differences in platelet concentration, hair density, and hair types were not statistically significant, but single-spin PRP may offer a simpler and slightly more effective approach. Further large-scale UK trials are needed to confirm findings.

A 37-year-old woman with recurring alopecia areata showed ‘segmented heterochromia’—striking lighter bands on individual hairs—and thinning where colour faded. This rare sign, typically linked to iron deficiency, was here connected to active AA. The pattern resembled ‘coudability hairs’ and suggests low-grade inflammation. UK dermatologists are urged to consider this overlooked clue when evaluating disease activity and potential need for further treatment.

China’s Hengrui Pharmaceutical has secured approval for Ivarmacitinib, a highly selective JAK1 inhibitor for severe alopecia areata, boasting a 40% response rate in trials—well above placebo. With additional approvals in dermatitis and arthritis, and pending FDA filings, Ivarmacitinib marks China’s rise in global biopharma. Its tolerability, broad application, and pricing edge position Hengrui as a strong player in the global autoimmune treatment landscape.

An eight-year-old boy with alopecia totalis showed remarkable hair regrowth within one month of starting daily baricitinib (2 mg). Genetic testing revealed a KRT74 variant, shared by family members without symptoms. However, his scalp showed heightened JAK1-STAT1 pathway activity and immune cell infiltration. The case highlights how JAK inhibitors like baricitinib may be especially effective in genetically predisposed alopecia areata cases, signalling promise for targeted treatments in paediatric autoimmune hair loss.

At the 2025 SDPA Conference, Dr Amy Spizuoco highlighted trichoscopy as a game-changer for diagnosing hair loss. This non-invasive tool improves accuracy in identifying both scarring and non-scarring alopecia, often removing the need for biopsies. It’s efficient, cost-effective, and helps detect early signs before permanent damage sets in. Spizuoco urged clinicians to adopt trichoscopy early in their practice to enhance care and speed up diagnosis—vital for patients facing hair loss.

A new study has highlighted the potential of high-frequency ultrasound (HFUS) in diagnosing and monitoring frontal fibrosing alopecia (FFA) — a scarring hair loss condition that mainly affects postmenopausal women. By examining 75 ultrasound scans from 15 patients, researchers detected significant scalp thinning and early signs of follicle damage. Notably, HFUS also revealed hidden inflammation in over a quarter of cases, which could help guide earlier and more targeted treatments. The findings support HFUS as a promising non-invasive tool for tracking disease progression and detecting subtle changes that might otherwise go unnoticed.

Pelage Pharmaceuticals’ experimental hair loss treatment PP405 has shown early success in a Phase 2a trial for androgenetic alopecia. Applied topically, PP405 works by targeting the root biological mechanism of hair growth rather than hormonal effects, setting it apart from existing treatments. Impressively, 31% of patients saw a hair density increase of over 20% within 8 weeks, with no systemic side effects observed. The treatment was well tolerated and even stimulated regrowth in bald areas. Phase 3 trials are set for 2026, marking a promising step in regenerative hair loss therapy.

A 23-year-old woman developed alopecia after hyaluronic acid (HA) filler was injected into her forehead. Despite early hyaluronidase treatment, hair loss worsened. A combination of concentrated growth factor (CGF), microneedling, and 5% minoxidil was used, leading to full regrowth within four months. A review of 19 similar cases revealed temple-area injections as the most common cause. Mechanisms include vascular blockage and inflammation. While HA fillers are popular and usually safe, this rare side effect highlights the importance of proper technique and early intervention. CGF-based therapy shows promise as a targeted treatment for filler-related hair loss.

A recent clinical study examined autologous follicular unit excision (FUE) in children with alopecia areata, evaluating safety and effectiveness. Children receiving the procedure had transplant success, improved hair growth, and minimal adverse effects. While long-term data remains limited, early results are encouraging, suggesting FUE could become a viable treatment option for young patients where conventional therapies have failed. The study emphasises the need for further paediatric-specific clinical trials.

A global analysis using data from 1990 to 2021 found new cases of alopecia areata jumped from 20.4 million to 30.9 million, although age‑standardised rates slightly dipped. It affects around 2% globally, disproportionately impacting women over 45. Beyond being an autoimmune condition, it’s linked to anxiety, depression and elevated job loss risk, with sufferers 82% more likely to be unemployed. The findings highlight the urgent need for research into regional variation, comorbidities and socioeconomic factors influencing disease burden.

A European study (Spain, Germany, France & UK) reviewed 335 patients with significant scalp hair loss (≥50%). Despite adults showing slightly more hair loss, adolescents (avg. 15 yrs) recorded higher Dermatology Life Quality Index scores (22.1 vs 18.2). Nearly all young patients (98%) reported ‘very large’ to ‘extremely large’ life impact, compared with 80% of adults. The data underline how alopecia profoundly affects adolescents’ self-esteem and daily wellbeing, urging better tailored support for teenage sufferers.

A recent literature review highlights the strong connection between mental health disorders and various forms of hair loss, including alopecia areata and trichotillomania. The study emphasizes that psychological stress can both trigger and result from hair loss, creating a challenging cycle for sufferers. For UK individuals, this underscores the importance of integrated care approaches that address both the physical and emotional aspects of hair loss.

A decade-long study has found that azathioprine, an immunosuppressive drug, achieved a 93% average hair regrowth rate in patients with moderate to severe alopecia areata. The trial, involving 63 participants, noted that side effects were generally mild and manageable. Given its established use in other autoimmune conditions, azathioprine could offer a cost-effective treatment option for UK patients facing limited access to newer therapies.

New research reveals your scalp is home to a complex microbiome that deeply affects hair health. Imbalances in bacteria and fungi populations can trigger dandruff, inflammation, and even hair thinning. UK trichologists are now looking at microbiome-balancing shampoos and treatments as the next big thing in tackling hair loss at its microbial roots.

South Korean researchers and cosmetic firms are pivoting towards scalp care, recognising its vital role in preventing hair loss. Using probiotics, microbiome analysis, and anti-inflammatory formulas, they aim to create products that treat the scalp like facial skin. This innovation may soon benefit British consumers, as K-beauty trends and biotechnology converge to redefine haircare from root to follicle.

Psoriasis, traditionally viewed as a skin condition, is now recognised for its association with increased cardiovascular disease risk. Medical guidelines recommend cardiovascular risk screening for all psoriasis patients, especially those with moderate to severe forms, to address this systemic health issue comprehensively.

Emerging research emphasizes the importance of the scalp microbiome—a community of bacteria, fungi, and yeast—in maintaining hair health. Imbalances in this ecosystem have been linked to conditions like dandruff and hair loss. Understanding and nurturing the scalp microbiome could lead to innovative treatments for various scalp disorders.

A recent study highlights the potential of oxyresveratrol, a compound from the Artocarpus lakoocha tree, in promoting hair growth. In both human cell cultures and mouse models, oxyresveratrol enhanced hair follicle cell proliferation and reduced inflammation, indicating its promise as a natural treatment for androgenetic alopecia.

Mounjaro, a medication for type 2 diabetes and weight management, has been linked to hair loss in some users. Reports suggest that rapid weight loss and nutritional deficiencies, rather than the drug itself, may disrupt hair growth cycles, leading to conditions like telogen effluvium. Experts advise that a balanced diet and medical supervision are crucial when using such medications to mitigate potential side effects.

The European Medicines Agency has issued new safety measures following reports of suicidal thoughts in users of finasteride (1 mg) used for hair loss. A patient card and updated warnings are now mandatory. Although dutasteride showed no confirmed link, similar cautionary language is advised. These developments are especially relevant for UK men considering treatment for male pattern baldness.

Dermatology Times reports a shift towards personalised strategies for alopecia areata, with JAK inhibitors like baricitinib and ritlecitinib showing promising real-world efficacy, particularly in severe and longstanding cases. UK clinicians are increasingly favouring a stepwise approach that combines systemic therapies with patient lifestyle and emotional support.

A 2024 study published on PubMed identifies “macular alopecia,” a newly recognised form of alopecia areata presenting as small, round patches under 1 cm. This finding broadens the diagnostic spectrum and underscores the importance of accurate clinical recognition, especially in UK dermatology settings where misdiagnosis as tinea capitis or trichotillomania may delay treatment.

Turkish dermatologists evaluated 390 adults with androgenetic alopecia seen in 2023‑24. Hairdex‑48 scores showed men endured markedly greater emotional and functional impairment than women, with 39 % of male cases deemed severe. Balding that began before age 20 imposed the harshest psychological burden, slashing self‑confidence and intensifying stigma. Although 69 % trawled Google, TikTok or Instagram for hair‑loss tips, social‑media use neither altered treatment choices nor lightened distress. Researchers call for clearer, evidence‑based online guidance—a timely reminder for UK GPs, trichologists and influencers to tackle misinformation head‑on.

A Brazilian prospective split‑scalp trial found methotrexate delivered by micro‑infusion (MMP®) can calm inflammation in frontal fibrosing alopecia (FFA). Seventeen women received three monthly sessions on one half of the hairline; treated areas showed less redness, scaling and itch, and 95 % were satisfied, while laboratory monitoring revealed no safety concerns. Hair density did not increase, yet disease activity appeared to stabilise where conventional tablets or topicals often fail. UK dermatologists might explore the technique for recalcitrant FFA, though larger randomised studies are needed before NHS adoption.

America’s FDA issued a safety alert over compounded topical finasteride lotions promoted by telehealth brands. Thirty‑two men have reported serious adverse events since 2019, including depression, dizziness, insomnia and lasting sexual dysfunction—effects already known from the oral drug. No topical finasteride is FDA‑approved; inadvertent skin‑to‑skin transfer and risks to unborn male foetuses are additional concerns. The UK’s MHRA likewise licences only tablet formulations, so Britons sourcing these products online should demand clear risk information and proceed with caution.

An international electronic‑health‑record study of 25,464 matched adults with psoriasis shows biologic injections targeting TNF‑α, IL‑17 or IL‑23 cut the 5‑year incidence of cardiovascular disease to 11 % versus 16 % on standard oral tablets (hazard ratio 0.62). Risks of stroke, heart failure and other major cardiac events all dropped, whereas IL‑12/23 inhibitors offered no clear benefit. Although observational, the data bolster the case for earlier biologic use within UK dermatology pathways to tackle both skin inflammation and the nation’s cardiometabolic burden.

New US research shows that the nature of a patient’s scalp discomfort can pinpoint the type of scarring (cicatricial) alopecia they have. Analysis of more than 400 cases found itching, burning and tenderness most often signalled lymphocytic forms such as lichen planopilaris or frontal fibrosing alopecia, whereas pain, pustules and discharge hinted at neutrophilic variants like folliculitis decalvans. Central centrifugal cicatricial alopecia, meanwhile, correlated with tightness and breakage around the crown. Researchers urge UK clinicians to take fuller symptom histories so patients receive a faster, subtype‑specific treatment plan.

A recent study has found that individuals experiencing transient hair shedding after starting minoxidil treatment for alopecia may see better long-term results. This temporary increase in hair loss, often a concern for patients, appears to indicate that the medication is effectively stimulating hair follicles. The research suggests that those who undergo this initial shedding phase are more likely to achieve significant hair regrowth over time. Experts advise patients to persist with minoxidil therapy despite early shedding, as it may be a positive sign of the treatment’s efficacy.

A recent study by the University of British Columbia suggests that semaglutide, the active ingredient in weight loss drugs like Wegovy, may elevate the risk of hair loss. Researchers found that individuals using semaglutide experienced higher incidences of hair shedding compared to those on alternative weight loss medications such as bupropion-naltrexone. The study indicates that this risk is more pronounced in women. Experts believe rapid weight loss induced by semaglutide may stress the body, disrupting the natural hair cycle. They recommend maintaining adequate nutrition, particularly protein intake, to mitigate this side effect.

Recent research indicates that low-dose oral minoxidil, commonly used to treat hair loss, may not be safe for individuals with systemic lupus erythematosus (SLE). The study highlights potential adverse effects, including exacerbation of lupus symptoms and increased risk of hypertension. Given the prevalence of SLE in the UK, patients are advised to consult their healthcare providers before considering minoxidil as a treatment option. This underscores the importance of personalised medical advice in managing hair loss among those with autoimmune conditions.​

A recent study has identified the Tru9I variant in the vitamin D receptor (VDR) gene as a potential genetic marker for vitamin D deficiency in individuals with alopecia areata (AA), an autoimmune condition causing hair loss. The research revealed that patients with AA carrying the Tru9I variant had significantly lower serum vitamin D levels and reduced VDR gene expression compared to those without the variant. This discovery suggests that genetic screening for the Tru9I variant could aid in early detection and management of vitamin D deficiency in AA patients, potentially improving treatment outcomes.

A recent study by NYU Langone Health reveals that low-dose doxycycline is as effective as higher doses in treating lymphocytic scarring alopecia, a rare autoimmune condition causing permanent hair loss. Patients on 20 milligrams twice daily experienced similar improvements in hair retention and scalp inflammation as those on 100 milligrams twice daily. Notably, only 12% of the low-dose group reported side effects like nausea, compared to 23% in the high-dose group. This finding suggests UK patients could achieve effective treatment with reduced side effects by opting for lower antibiotic doses.

Recent research indicates that Thermus thermophilus fermentation extract (TTFE) may effectively promote scalp health and stimulate hair growth in individuals with androgenic alopecia. TTFE contains extremophilic proteins and polyamines like spermidine and spermine, known to extend lifespan and delay aging. In a clinical trial, TTFE demonstrated a 96.88% improvement in hair growth, attributed to its anti-inflammatory properties and ability to enhance scalp health. This novel approach offers hope to many in the UK affected by pattern hair loss, presenting a potential alternative to existing treatments.

​Chronic kidney disease (CKD) frequently leads to alopecia, affecting up to 38% of patients undergoing dialysis. The condition disrupts the hair growth cycle, pushing hair into the shedding phase. Contributing factors include nutritional deficiencies, metabolic imbalances, and medication side effects. Addressing these underlying issues can often reverse hair loss. For UK patients with CKD experiencing alopecia, consulting healthcare providers for tailored treatment plans is advisable.

Researchers from IOCB Prague and Johns Hopkins University have developed itaconate-based prodrugs showing promise in treating alopecia areata, an autoimmune disorder causing patchy hair loss. These compounds, derived from naturally anti-inflammatory itaconic acid, effectively penetrate cells and release active ingredients in the skin, as demonstrated in mouse studies. Notably, these prodrugs may be administered orally, offering a potential alternative to current treatments like corticosteroids, which often have adverse effects. This advancement could benefit the estimated 2% of individuals affected by alopecia areata, including many in the UK.

Chinese researchers have identified key genes linked to alopecia areata (AA), an autoimmune condition causing hair loss. Their study highlights the significant roles of immune cells, particularly T cells and natural killer (NK) cells, in attacking hair follicles via melanocytes. Advanced computational methods, including machine learning, pinpointed these gene targets. Furthermore, molecular docking simulations suggest potential therapeutic agents that could interact with these targets, paving the way for novel treatments. This breakthrough offers hope to the millions affected by AA, including those in the UK, by advancing targeted therapy development.

Scientists at the University of California, Los Angeles (UCLA) have unveiled a method to rouse dormant hair follicles, offering renewed hope to those experiencing hair loss. By manipulating signalling molecules that regulate follicle activity, researchers can effectively bring “hibernating” cells back to life. If these findings prove successful in human trials, they could revolutionise treatment for various types of alopecia and lessen reliance on invasive procedures. Given that millions across Britain struggle with thinning hair, this innovative approach may pave the way for a safer, more effective solution.

A recent study published on medRxiv indicates a potential link between semaglutide—a medication commonly prescribed for weight loss—and an increased risk of hair loss, particularly among women. The retrospective cohort study analysed data from 1,926 semaglutide users and 1,348 bupropion-naltrexone users, finding that women on semaglutide had a 2.08 times higher risk of experiencing hair loss compared to those on the alternative medication. The researchers suggest that rapid weight loss induced by semaglutide may contribute to this side effect, emphasizing the need for further studies to confirm these findings.

A recent case report published in Cureus details a rare presentation of comedonal discoid lupus erythematosus (DLE) in a 52-year-old male. The patient exhibited hypertrophic plaques with follicular plugging and open comedones on the scalp, leading to scarring alopecia. Dermatoscopic examination revealed telangiectasias and scattered arborizing vessels. This atypical acneiform manifestation of DLE poses diagnostic challenges, emphasizing the need for clinicians to consider DLE in patients presenting with similar scalp lesions to ensure timely and appropriate management.

​Recent findings from the phase 3 BRAVE-AA-PEDS trial reveal that baricitinib, a Janus kinase (JAK) inhibitor, induces rapid hair regrowth in adolescents with severe alopecia areata (AA). This trial, the largest of its kind focusing on this demographic, enrolled 250 patients, many experiencing near-total scalp hair loss. Despite presenting with more severe disease compared to adults, adolescents responded positively to baricitinib, highlighting its potential as an effective treatment for this challenging condition.

A recent study presented at the 2025 American Academy of Dermatology Annual Meeting suggests that glycemic control may influence outcomes in central centrifugal cicatricial alopecia (CCCA). The research indicates that patients using GLP-1 receptor agonists (GLP-1 RAs), medications commonly prescribed for diabetes management, experienced significant reductions in scalp pain and tenderness. Additionally, these patients showed trends toward disease stabilization, highlighting a potential link between metabolic health and CCCA progression. ​

A recent study published in the International Journal of Molecular Sciences reveals that veratric acid (VA), a compound prevalent in various fruits and vegetables, may combat hair loss by stimulating human hair follicle dermal papilla cells (HFDPCs). The research indicates that VA enhances HFDPC proliferation, boosts hair-inductive properties, and reduces cellular ageing and apoptosis. These findings suggest VA’s potential as a natural therapeutic agent for promoting hair growth and addressing hair loss concerns.

This Cureus study introduces new, precise approaches for assessing hair regrowth and scalp health in patients with androgenetic alopecia. Researchers focus on standardising measurements of hair keratin levels and evaluating scalp condition to enhance treatment outcomes. By refining imaging techniques and analytical benchmarks, they aim to provide dermatologists worldwide with robust data for personalised care. Emphasising consistent assessment unifies clinical practices, advancing potential therapies that benefit those coping with hair loss. The study highlights the importance of innovative, evidence-based strategies to meet the growing need for effective hair restoration solutions.

A recent study has established a genetic link between androgenetic alopecia (AGA) and an increased risk of depression. Utilizing Mendelian randomization analysis, researchers found that while AGA elevates the likelihood of developing depression, the reverse is not true—depression does not increase the risk of AGA. Shared factors such as genetics, hormonal changes, stress, and immune system dysregulation may contribute to both conditions. These findings underscore the importance of early psychological support and holistic treatment approaches for individuals experiencing hair loss.

A recent bidirectional Mendelian randomization study has identified a causal link between specific blood metabolites and female pattern hair loss (FPHL). Researchers analysed data from genome-wide association studies, focusing on 1,400 blood metabolites. They discovered that 23 metabolites and 4 metabolic ratios are associated with FPHL, with fructose and mannose metabolism being notably implicated. These findings offer new insights into FPHL’s metabolic mechanisms, potentially guiding future diagnostic and therapeutic approaches.

A recent study by King’s College London researchers has identified a significant gene-gene interaction that increases the risk of frontal fibrosing alopecia (FFA), a distressing condition leading to irreversible hair loss. The study found that specific genetic differences within the major histocompatibility complex interact with the ERAP1 gene, elevating FFA risk. This phenomenon, known as epistasis, has also been observed in autoimmune diseases like psoriasis and ankylosing spondylitis. These findings enhance our understanding of FFA’s genetic underpinnings and could inform future therapeutic strategies.

A recent study has found a significant link between male pattern baldness (MPB) and elevated levels of the oral gas dimethylsulfide (CH₃SCH₃) in elderly Japanese men. The research indicates that men with severe MPB and concurrent gastrointestinal diseases, hypertension, or high cholesterol exhibited notably higher CH₃SCH₃ levels. These findings suggest that monitoring CH₃SCH₃ could aid in understanding the relationship between hair loss and systemic health issues.

Recent research has identified a novel gene-to-gene interaction that increases the risk of developing alopecia, a condition characterized by hair loss. This discovery enhances our understanding of the genetic factors contributing to alopecia and may pave the way for more targeted treatments in the future.

Recent studies suggest that botulinum toxin (BTX) injections may offer a promising and safe treatment for androgenetic alopecia (AGA). AGA is characterized by the progressive miniaturization of hair follicles, often driven by dihydrotestosterone (DHT) sensitivity and perifollicular micro-inflammation. BTX injections appear to work by improving scalp blood flow and reducing DHT-related follicular damage, offering a novel therapeutic approach. Reported adverse effects were minor and included headaches and mild injection-site irritation. However, rigorous clinical trials are necessary to confirm the long-term efficacy and safety of this treatment in clinical practice.

At the 2025 South Beach Symposium, Dr. Naiem Issa emphasized a holistic, patient-centered approach to hair loss treatment, integrating medical and interventional therapies tailored to individual needs. He highlighted the effectiveness of platelet-rich plasma (PRP) therapy, noting its widespread use among suitable candidates, while cautioning against its application in patients with contraindications. For scarring alopecia, Dr. Issa recommended focusing on reducing inflammation and promoting hair regeneration, acknowledging potential risks like “kebnerization.” He also pointed to emerging treatments, such as laser therapies and mesenchymal stem cells, as promising avenues requiring further research.

In a recent podcast episode titled “Going bald in an increasingly hairy world” The Guardian explores the societal pressures and personal challenges associated with male baldness. The discussion highlights the rising popularity of hair transplants and preventative treatments, leading many men to opt out of baldness. The conversation delves into why accepting this natural part of aging remains difficult for many. The episode features insights from writer Stuart Heritage and producer Rudi Zygadlo, who share their perspectives on the evolving attitudes toward hair loss.

Alopecia areata is an autoimmune disorder leading to non-scarring hair loss, primarily on the scalp but potentially affecting all hair-bearing areas. Recent insights into its complex pathophysiology have paved the way for advanced treatments. Notably, Janus kinase (JAK) inhibitors have emerged as a promising therapeutic option, offering hope for more effective management of this condition.

Emerging research suggests a potential link between alopecia areata and deficiencies in serum vitamin D and zinc levels. While the exact relationship remains under investigation, maintaining adequate levels of these nutrients may play a role in hair health. Individuals experiencing hair loss should consult with healthcare professionals to assess their nutritional status and consider appropriate interventions.

A recent U.S. study indicates that low-dose oral minoxidil is both safe and effective for treating hair loss in breast cancer survivors. The retrospective cohort study involved 51 women who began minoxidil treatment during or after their cancer therapies, including chemotherapy, surgery, or radiation. Within three to six months, all participants experienced either hair regrowth or stabilization of hair loss. Notably, while 57% reported side effects—primarily increased hair growth in unintended areas—there were no instances of pericardial complications, and only four cases of tachycardia or hypotension. These findings suggest that minoxidil can be a viable option for managing alopecia in this patient group.

A recent study published in the Journal of Cosmetic Dermatology analyzed data from the U.S. Food and Drug Administration’s Adverse Event Reporting System to assess the link between oral minoxidil (OM) and pericardial effusion (PE). Among 2,747 reports of OM use, only 35 cases (1.3%) involved PE, indicating it is an infrequent side effect. Notably, the occurrence of PE was not found to be dose-dependent. The study emphasizes the importance of thorough medical evaluations before prescribing OM for hair loss to identify any pre-existing conditions that could elevate the risk of PE.

A recent pilot study published in the Journal of the European Academy of Dermatology and Venereology has identified superficial cryotherapy as a promising alternative treatment for patchy alopecia areata. The research compared two cryotherapy protocols—10-second and 20-second applications—to standard triamcinolone acetonide (TA) injections. Findings revealed that a 20-second application in two freeze-thaw cycles resulted in significant hair regrowth, comparable to TA injections, while the 10-second protocol showed no notable improvement. This suggests that superficial cryotherapy, particularly with optimized parameters, could offer an effective, less invasive treatment option for patients with patchy alopecia areata.

A recent study published in Dermatologic Therapy highlights the effectiveness of ultraviolet-induced fluorescence trichoscopy (UVFT) in distinguishing between scarring and non-scarring types of hair loss. Researchers observed that scarring alopecias commonly exhibit white-blue perifollicular fluorescence and dark perifollicular areas, while non-scarring alopecias are characterized by pink-red or green follicular fluorescence and dark follicular dots. These findings suggest that UVFT can serve as a valuable diagnostic tool, aiding clinicians in accurately identifying various forms of alopecia and informing appropriate treatment strategies.

A recent systematic review and meta-analysis evaluated the efficacy of combining minoxidil with low-level laser therapy (LLLT) for treating androgenic alopecia. The findings indicate that adding LLLT to minoxidil does not enhance treatment outcomes in terms of hair count or diameter compared to using minoxidil alone. This suggests that minoxidil remains a potent standalone treatment for hair loss, potentially eliminating the need for the more complex and costly addition of LLLT.

A recent study in the British Journal of Dermatology explores the evolution of long scalp hair in humans. Researchers suggest that the ability to grow long hair emerged over 300,000 years ago, possibly aiding in cooling the sun-exposed heads of early humans in Africa. Beyond thermoregulation, long hair likely played a role in social communication, signaling age, health, and status. The study proposes that variations in hair length are due to evolutionary changes in the hair growth cycle, particularly the active growth phase known as anagen. Understanding these mechanisms could provide insights into hair growth disorders.

New research highlights a potential overlap between alopecia areata (AA) and other inflammatory conditions, emphasising the importance of screening for co-occurring diseases. Preliminary findings suggest shared immune pathways could raise the risk of conditions such as rheumatoid arthritis. According to experts, recognising these links early on can lead to improved patient outcomes and more comprehensive treatment strategies. Further studies are under way to confirm these associations and uncover targeted therapies, offering renewed hope for those affected by AA in the UK and beyond.

In a newly published study, a nutraceutical supplement has proven effective and safe in addressing male hair thinning. Researchers documented improvements in hair density and quality, highlighting the supplement’s potential to provide a non-invasive solution for UK men worried about receding hairlines. By delivering a range of vitamins and other beneficial ingredients, the product aims to bolster scalp health and encourage hair growth. Experts suggest it could be a valuable addition to current treatment options, offering hope for those seeking a less intrusive approach to hair loss.

A recent class action lawsuit in the US alleges that Mielle Organics and its parent company, Procter & Gamble, knowingly sold products linked to hair loss and scalp issues. Plaintiffs claim misleading marketing and inadequate safety warnings led to unexpected side effects. With Mielle products popular among British consumers, the legal battle’s outcome may influence consumer protection measures and shape future demands for transparency in global haircare.

New findings highlight specific factors that may signal a worse outcome for those with alopecia areata. Researchers found older age, repeated episodes, and severe hair loss at onset all linked to less favourable treatment results. The study encourages earlier medical attention and personalised strategies to mitigate progression, improve regrowth prospects, and enhance quality of life. With alopecia areata affecting around 2% of Britons, raising awareness is crucial. Armed with this knowledge, both patients and healthcare providers in the UK can better tackle the condition, exploring options like tailored therapies and lifestyle adjustments.

New evidence suggests that zinc, copper, and vitamin D play a pivotal role in managing alopecia areata. Researchers found that deficiencies in these nutrients could worsen hair loss and hinder regrowth, making regular monitoring essential. For Britons, limited sun exposure can further impact vitamin D levels, highlighting the importance of a balanced diet or supplements. Experts recommend checking micronutrient levels and using personalised treatment plans to support healthy hair and improve overall wellbeing. By staying proactive about nutrition, those affected in the UK can address potential deficiencies and boost their chances of better hair health.

Many younger Britons are spotting grey hairs earlier, and experts suggest rising stress and mineral deficiencies could be to blame. According to the article, Millennials and Gen Z may be especially vulnerable if their diets lack key nutrients like iron, zinc, and B vitamins. While genetics can play a role, hectic lifestyles and poor nutrition may speed up the greying process. Healthcare professionals advise balanced eating habits, stress management, and speaking to specialists about hair concerns. By addressing underlying causes and staying proactive, younger generations in the UK could slow or prevent premature greying.

Infants born to mothers with alopecia areata may face a higher risk of complications, according to recent findings. This includes potential issues like preterm birth and lower birth weight, underscoring the need for tailored prenatal and postnatal care for expecting mothers with the condition. Experts suggest that enhanced monitoring and close collaboration with healthcare providers can help mitigate these risks. For British families managing alopecia areata, it’s crucial to discuss any concerns with a specialist early on. By staying vigilant and planning proactively, better outcomes are within reach for both mothers and their babies.

An unexpected case report details how baricitinib, a JAK inhibitor used to tackle alopecia universalis, led to widespread white hair regrowth instead of its usual colour. Researchers suggest the drug’s immune-modulating effects could also influence pigmentation, resulting in this striking outcome. While the patient experienced substantial improvement in hair density, the shift in colour underscores the complexities of alopecia treatment. Experts call for further studies to better understand the link between immune pathways and hair pigmentation. For Britons with severe hair loss, these findings highlight the importance of careful monitoring and personalised therapy.

Cesare Ragazzi was a visionary in hair restoration, pioneering advanced scalp prosthetics that provided natural-looking, non-surgical solutions. His innovative CNC system—combining 3D scanning with biomedical materials—helped countless individuals regain confidence. Ragazzi’s focus on comfort and durability propelled his methods to worldwide acclaim, resonating strongly with Britons seeking discreet, effective hair replacement. His enduring legacy stems from ongoing research and product refinement, offering hope to those dealing with persistent hair loss. By merging science, empathy, and a relentless pursuit of quality, Ragazzi raised the bar for future innovations in the field.

Recent reports indicate that infants exposed to minoxidil, a common hair loss treatment, may develop hypertrichosis, characterized by excessive hair growth. In one case, a baby developed increased hair on the back, legs, and thighs after the father applied 5% topical minoxidil and spent extended time with the child. Upon discontinuing the medication, the infant’s symptoms resolved. A review identified 11 similar cases, suggesting that infants can absorb minoxidil through direct or indirect contact with treated caregivers. This highlights the need for caution when using minoxidil around young children.

Alopecia areata, an autoimmune disorder causing hair loss, is frequently associated with comorbid conditions that can exacerbate its impact on patients’ quality of life. Notably, individuals with alopecia areata have a higher prevalence of autoimmune diseases, such as thyroid disorders and vitiligo, as well as psychiatric conditions, including depression and anxiety. Regular monitoring for these comorbidities is essential to ensure comprehensive care and improve patient outcomes.

A recent study indicates that intermittent fasting may impede hair growth. Experiments with mice showed that those on intermittent fasting regimens experienced slower hair regrowth compared to those with unrestricted diets. A small human trial mirrored these findings, with participants fasting 18 hours daily exhibiting an 18% reduction in hair regrowth speed. Researchers suggest that fasting-induced metabolic changes could adversely affect hair follicle stem cells, leading to diminished hair growth.

A recent study from NYU Langone Health indicates that low-dose oral minoxidil is both safe and effective for treating hair loss in breast cancer patients during or after chemotherapy. Among 51 women studied, all experienced hair regrowth or stabilization within three to six months, without significant cardiovascular side effects.

A recent study indicates that microneedle transdermal delivery of compound betamethasone is as effective as traditional intralesional injections for treating mild to moderate alopecia areata, with patients experiencing significantly less pain.

A recent study highlights that baricitinib and ritlecitinib, both Janus kinase (JAK) inhibitors, show similar effectiveness in treating severe alopecia areata (AA). Higher doses of baricitinib (4 mg) and ritlecitinib (200 mg or 50 mg) delivered better hair regrowth results, demonstrating their potential as impactful therapies. The findings offer hope for patients with severe AA, but researchers emphasize the need for further studies to evaluate long-term safety and efficacy. These advancements signal a promising future for managing this challenging condition, offering new options for UK patients seeking effective treatment solutions.

A new study highlights a significant link between alopecia areata (AA), an autoimmune hair loss condition, and coeliac disease. Researchers found AA patients are nearly twice as likely to have coeliac disease compared to those without AA, with the risk particularly elevated in individuals over 40. The study underscores the importance of screening AA patients for coeliac disease to prevent complications from undiagnosed gluten intolerance. Raising awareness in the UK about this connection can help improve patient outcomes and encourage timely intervention through appropriate dietary and medical management.

A survey shows 23% of mothers are surprised by postpartum hair loss, a condition often left undiscussed. During pregnancy, elevated estrogen levels enhance hair growth, but post-birth, the sudden hormonal drop triggers significant shedding, peaking around three to four months postpartum. Known as telogen effluvium, this temporary phase typically resolves within a year. Experts advise new mothers to focus on gentle hair care, a nutritious diet, and stress management to promote recovery. Greater awareness can help UK mothers prepare for this natural process, easing unnecessary stress and fostering open conversations about postpartum changes.

A recent study explored the link between alcohol use and androgenetic alopecia (AGA), the most common form of hair loss. Results indicated drinkers may be 1.4 times more likely to experience AGA compared to non-drinkers, though the association was not statistically significant. Researchers hypothesize that acetaldehyde, a byproduct of alcohol metabolism, could disrupt the scalp’s immune environment, potentially influencing hair loss. The study highlights the need for more rigorous research to confirm these findings. UK readers concerned about hair health may consider moderating alcohol intake while awaiting further insights.

The growing trend of medical tourism, including hair transplant procedures abroad, is creating challenges for airlines. Many UK patients travel internationally for affordable treatments but face post-operative complications during return flights. Airlines report increased requests for special assistance, including extra seating and medical care, straining resources and raising safety concerns. Issues such as swelling, bleeding, and limited mobility after surgeries can affect other passengers and flight operations. As medical tourism surges, particularly in popular destinations like Turkey, airlines are calling for greater awareness and planning to ensure the safety and comfort of all travelers.

Elithair’s note: Worried about travel plans after a hair transplant? We understand your concerns. Hair surgeries are considered keyhole procedures, often requiring just 24 hours of rest before you can safely fly; according to the UK Civil Aviation Authority (CAA). To ensure your comfort and confidence, we schedule a follow-up at our clinic the day after your procedure. Our expert team checks your recovery and provides personalised advice, so you’re ready to travel home with peace of mind.

A recent study indicates that metformin, commonly used for type 2 diabetes, may effectively treat central centrifugal cicatricial alopecia (CCCA). Patients with treatment-resistant CCCA experienced symptom improvement and favorable changes in gene expression after metformin therapy, suggesting its potential as a novel treatment option.

Researchers are examining the potential connection between alcohol intake and androgenetic alopecia (male pattern baldness). While the exact relationship remains unclear, excessive alcohol consumption is known to disrupt hormonal balance and nutrient absorption, factors that could influence hair health. Further studies are needed to determine whether reducing alcohol intake may help prevent or mitigate hair loss in affected individuals.

A recent study indicates that reducing the dosage of baricitinib from 4 mg to 2 mg daily can sustain hair regrowth in patients with alopecia areata. Participants who achieved significant hair regrowth on the higher dose maintained their progress after transitioning to the lower dose, with minimal adverse effects reported. These findings suggest that a reduced baricitinib dosage may effectively maintain treatment outcomes while potentially decreasing the risk of side effects.

A recent study highlights the efficacy of platelet-rich plasma (PRP) in improving hair transplant results for individuals with androgenetic alopecia. PRP enhances the transplant area’s microenvironment by promoting cell growth, inhibiting cell death, and stimulating new blood vessel formation, leading to improved hair growth and strength within three months. Patients receiving PRP exhibited higher follicle survival rates, quicker initial hair growth, and minimal postoperative complications, such as transient itching or folliculitis. The study underscores PRP’s potential to significantly boost hair transplant success.

Elithair’s note: All our hair transplant includes a free PRP session designed to boost your final outcome and support stronger, healthier hair growth.

An international expert panel has reached a consensus supporting the use of low-dose oral minoxidil as an effective treatment for various hair loss disorders, including androgenetic alopecia and alopecia areata. The panel’s findings indicate that oral minoxidil offers advantages over topical formulations, such as lower cost, greater convenience, and reduced scalp irritation. However, they advise caution for individuals with certain medical conditions, including heart-related issues, and recommend that treatment decisions be tailored to each patient’s specific circumstances.

A recent study published in the Journal of the American Academy of Dermatology reports that ritlecitinib effectively maintains hair regrowth in individuals with alopecia areata over a 48-week period. Patients who responded to treatment by week 24 continued to show improvement, while nearly one-third of initial non-responders achieved significant hair regrowth with prolonged therapy. These findings highlight ritlecitinib’s potential as a long-term treatment option for sustained hair regrowth in alopecia areata patients.

A recent study indicates that exposure to exogenous gonadocorticoids—hormonal treatments such as contraceptives, hormone replacement therapy (HRT), and anabolic steroids—is associated with an increased risk of developing lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA). The research, analyzing data from 2004 to 2024, found that women using hormonal contraceptives, exogenous androgens, or anabolic steroids had higher odds of LPP/FFA compared to controls. Similarly, men exposed to exogenous androgens showed a greater likelihood of these conditions. The findings suggest that hormonal therapies may influence the onset of certain types of alopecia.

A recent study has found that women using levonorgestrel-releasing intrauterine devices (IUDs) are at a higher risk of developing dermatological conditions such as acne, alopecia, and hirsutism compared to those using non-hormonal copper IUDs. The research, which analysed data from 1,224 women aged 18 to 60 over a decade, revealed that new instances of these conditions were more prevalent among hormonal IUD users. These findings suggest that the androgenic effects of levonorgestrel may contribute to these skin and hair disorders.

University of Limerick graduate Olivia Humphreys has won the 2024 James Dyson Award in the Medical Devices category for her invention, Athena—a portable, cost-effective scalp-cooling device designed to prevent hair loss during chemotherapy. Inspired by her mother’s cancer treatment, Humphreys developed Athena to offer patients greater mobility and affordability compared to existing solutions. The device utilizes thermoelectric technology to cool the scalp, reducing chemotherapy-induced hair loss. This marks the first time an Irish entrant has secured the global award since its inception in 2006.

A recent study indicates that individuals with inflammatory bowel disease (IBD) undergoing anti–tumor necrosis factor (TNF) therapy are at a heightened risk of developing alopecia areata compared to those not on such treatment. The research found no significant difference in alopecia improvement between patients who discontinued or continued their IBD therapy. However, severe cases of alopecia areata showed less improvement than non-severe cases. These findings suggest a potential association between anti-TNF therapy and alopecia areata onset in IBD patients.

A study on pediatric alopecia areata highlights disparities in prevalence by race and ethnicity, with higher rates among South Asian, Filipino, and Black children compared to White children. Specific Asian subgroups, especially South Asian and Vietnamese, show elevated prevalence, revealing disparities. These findings underscore the need for culturally tailored treatment and increased awareness among healthcare providers.

A recent study shows a connection between alopecia areata and asthma, identifying the inflammatory protein IL-33 as a key link. Genetic analysis revealed that individuals with asthma have a higher risk of developing alopecia areata due to shared inflammatory pathways. Dupilumab, a drug that targets IL-33, may offer therapeutic potential for those suffering from both conditions. However, further studies in diverse populations are necessary.

A UK survey reveals that most dermatologists prefer corticosteroids and minoxidil as first-line treatments for alopecia areata (AA) and female pattern hair loss (FPHL). Despite recent advances, including promising JAK inhibitors, these options aren’t yet widely accessible through the NHS, limiting their use. The COVID-19 pandemic also disrupted services, increasing challenges in treatment access. Findings emphasize the need for improved guidelines and NHS support for newer therapies.

A phase 2a trial revealed that brepocitinib, a TYK2/JAK1 inhibitor, can significantly reduce inflammation and CCL5 expression in cicatricial alopecia (CA), a scarring hair loss condition. Patients treated with brepocitinib saw improved clinical severity scores over 24 weeks, showing effective downregulation of fibrosis markers and inflammation. Additionally, brepocitinib maintained a strong safety profile, making it a potential treatment for CA.

At the recent Fall Clinical Dermatology Conference, Dr. James Song shared advanced strategies for treating alopecia areata, difficult dermatoses, and emerging topical treatments. Highlights included using DCPC for severe alopecia, deucravacitinib for lupus, and upadacitinib for dermatomyositis. Dr. Song also discussed promising non-steroidal topicals like ruxolitinib and roflumilast for conditions like atopic dermatitis, offering new, effective options for patients needing alternatives to steroids.

Recent research reveals a strong association between postpartum hair loss and anxiety in new mothers. Women experiencing significant hair shedding after childbirth reported higher anxiety levels, according to the Generalized Anxiety Disorder 2-item (GAD-2) scale. The study identified factors such as first-time motherhood, severity of hair loss, and insomnia as significant predictors of anxiety.

A case report reveals that a tick bite triggered diffuse alopecia areata-like hair loss in a 28-year-old woman, spreading from the initial bite site to cover her entire scalp within a month. Standard treatments failed, but a regimen of prednisone and baricitinib successfully promoted hair regrowth. This unusual case highlights tick saliva’s ability to provoke immune responses leading to hair loss, typically around the bite area.

A recent study reports that deuruxolitinib (Leqselvi) effectively supports sustained hair regrowth in severe alopecia areata over a 68-week period. Results from clinical trials showed significant improvements, with nearly half of the participants achieving meaningful hair density increases. Additionally, deuruxolitinib was well-tolerated, with a low incidence of side effects, making it a potential long-term option for managing severe alopecia areata.

Many common beauty practices can damage eyelashes, including false eyelashes, curlers, and certain cosmetics. To promote healthier lashes, experts recommend gentle handling and products like elongating primers and conditioners to minimize breakage and support growth. For those considering permanent eyeliner, it’s essential to weigh potential long-term effects, as tattoos can fade or change over time.

A recent trial has found that combining dupilumab and abrocitinib significantly improves severe atopic dermatitis (AD) symptoms in children, enhancing both disease stability and quality of life. Three pediatric patients who previously found little relief with standard treatments experienced reduced flare-ups and itching when using the two drugs together. Despite positive results, accessing this therapy can be challenging due to the extensive approval process. Further research is needed to evaluate its long-term safety.

A recent Telegraph article reports the tragic story of a student who took his life following complications from a botched beard transplant. Seeking a fuller beard, he underwent surgery abroad, but unsatisfactory results and visible scarring left him feeling deeply distressed. This incident highlights the importance of thoroughly researching and choosing reputable clinics for cosmetic procedures to avoid severe emotional and physical consequences.

Our Advice: At Elithair, we work exclusively with top specialists. Our medical teams receive ongoing training to ensure hair treatments meet the highest international standards. Each procedure is performed with precision to guarantee optimal results. We have also published a guide to help our patients identify and avoid high-risk hair clinics, empowering them to make informed choices for their hair health.

Recent research has identified genetic links between alopecia areata (AA) and various trace elements, serum metabolites, and inflammatory markers. A genetic analysis suggests that higher levels of copper may protect against AA, while certain inflammatory markers increase the risk. These findings open the door to potential new treatments and preventive strategies. However, further research is required to clarify the exact biological mechanisms involved. This study primarily focused on European populations, so the findings may not apply universally. The research highlights the importance of understanding both genetic and environmental factors in managing AA.

A new condition, dubbed the “headspin hole“, has been identified in breakdancers. The condition manifests as scalp damage, including a lump and hair loss, due to repetitive headspins. This repetitive friction and pressure cause both aesthetic and health concerns, with some cases leading to the need for medical intervention. The report highlights the importance of protective measures and early treatment to prevent long-term damage to the scalp.

The European Medicines Agency (EMA) has initiated a safety review of hair loss drugs, including finasteride and dutasteride, amid concerns about their potential link to suicidal thoughts and behaviors. These medications are commonly used to treat androgenic alopecia (male-pattern baldness) and benign prostatic hyperplasia. The review follows reports of psychiatric side effects, such as depression and suicidal ideation. The EMA’s review will assess all available data to determine if these medications’ benefits continue to outweigh the risks and may result in changes to their usage recommendations across the EU.

Alopecia areata (AA) can severely affect the mental health of young people, leading to lowered self-esteem, body image issues, and social anxiety. A recent review highlights the emotional distress and isolation often experienced by children and adolescents with AA, emphasizing the need for psychological support alongside dermatological care. Integrating psychodermatology—combining skin and mental health care—can help address these issues. With AA typically manifesting during critical developmental years, comprehensive care is essential to support their overall well-being.

Ashwagandha, a powerful adaptogen, may help reduce hair loss by lowering cortisol levels, a stress hormone linked to hair thinning. According to Healthline, its antioxidant properties and ability to improve scalp circulation could promote healthier hair growth. However, while some evidence supports its potential benefits, more research is needed to confirm its effectiveness in preventing or reversing hair loss. Consult with a healthcare provider before using it as a treatment.

A recent study reveals that scalp cooling can help reduce persistent alopecia caused by chemotherapy. The technique, which cools the scalp to restrict blood flow to hair follicles during treatment, has shown promise in preventing long-term hair loss in cancer patients. Researchers highlight that this method could significantly improve the quality of life for those undergoing chemotherapy.

Female hair loss can result from hormonal imbalances, inflammation, nutrient deficiencies, and ageing. Common conditions include androgenetic alopecia, telogen effluvium, and autoimmune disorders. Preventative measures include natural treatments like saw palmetto, pumpkin seed oil, and anti-inflammatory ingredients such as turmeric. Nutritional deficiencies, particularly in vitamins like D, iron, and B-complex, also play a role. Addressing these causes holistically, with both pharmaceutical and non-pharmaceutical options, is key.

New research suggests a potential causal relationship between hypothyroidism and alopecia areata (AA), while no such link was found with androgenetic alopecia (AGA). The study used Mendelian randomization and showed that people with hypothyroidism have a higher risk of developing AA. These findings may help resolve the ongoing debate about the connection between hypothyroidism and hair loss. More research is needed, but clinicians are encouraged to monitor thyroid function in patients with AA.

Researchers are set to investigate the effectiveness of rezpegaldesleukin for treating severe and very severe alopecia areata, an autoimmune condition that causes significant hair loss. Rezpegaldesleukin, an IL-2-based therapy, is designed to restore immune balance, potentially halting or reversing hair loss. The study aims to provide new treatment options for patients with advanced stages of the condition.

Some individuals have reported hair loss following COVID-19 vaccination, although no direct link has been confirmed. Hair loss could result from stress or conditions like telogen effluvium, triggered by the body’s immune response to the vaccine. Experts emphasize that the benefits of vaccination outweigh potential side effects. Hair loss is typically temporary, and those affected should consult healthcare professionals.

A new study suggests that injectable formulations combining dutasteride with growth factors can effectively treat androgenetic alopecia (AGA), a common cause of hair loss. The treatment led to significant hair growth improvements in men with AGA, providing a potential alternative to oral medications. While promising, further research is needed to confirm these findings. You can read the full details in the original article on Dermatology Advisor.

The European Medicines Agency (EMA) has launched a review of finasteride and dutasteride-containing medicines, commonly used to treat hair loss and benign prostatic hyperplasia. The review was prompted by concerns over potential links between these drugs and suicidal ideation. The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) will evaluate existing data to reassess the benefit-risk balance of these medications. For further details, you can access the original EMA document.

Atypical Central Centrifugal Cicatricial Alopecia (CCCA) is a rare type of hair loss affecting the scalp, often seen in women of African descent. Unlike typical CCCA, which leads to scarring and permanent hair loss, atypical cases may present with subtler symptoms and less scarring, making diagnosis and treatment challenging. Early detection and appropriate management are crucial for preventing irreversible damage. For further insights, read the original article on Medscape.

At the 2024 Skin of Color Update conference, experts emphasised the importance of accurate diagnosis and management of hair disorders in diverse populations. Dr. Susan Taylor highlighted central centrifugal cicatricial alopecia (CCCA), common in skin of colour patients, and its connection to scarring. Misdiagnosis often delays treatment, increasing emotional and physical burdens. Other conditions discussed included lichen planopilaris, frontal fibrosing alopecia, and traction alopecia, with an emphasis on modifying hair practices in culturally sensitive ways.

A recent review explores the safety and efficacy of low-dose oral minoxidil for paediatric patients experiencing hair loss, particularly those with alopecia. The study shows promising results, indicating that oral minoxidil may be safer than previously thought, with minimal side effects in children. Though traditionally used for adult hair loss, this review highlights its potential as a treatment for children suffering from alopecia, offering hope for families seeking effective solutions. More long-term research is needed to fully understand its impact and safety in younger patients.

Magnesium L-threonate, a form of magnesium known for its potential cognitive benefits, has sparked interest in the hair loss community. While magnesium plays a role in overall health, there is limited scientific evidence directly linking Magnesium L-threonate to hair regrowth. Some suggest that magnesium can help improve hair health by reducing inflammation and regulating calcium, which can influence hair follicles. However, further research is needed to confirm its efficacy for treating hair loss. As always, it’s important to consult a healthcare provider before starting new supplements.

Mielle Organics, a popular hair care brand, faced backlash after users reported experiencing hair loss and scalp issues allegedly caused by its Rosemary Mint Scalp & Hair Strengthening Oil. The product, originally marketed for natural hair types, went viral on TikTok, leading to increased sales among diverse groups. However, some users claimed adverse effects, sparking debates online. Mielle Organics responded by assuring the public of the product’s safety, citing no changes in its formula. Dermatologists recommend consulting a specialist before using new hair products, especially if experiencing unusual hair loss.

A new study highlights the effectiveness of combining compound glycyrrhizin (CG) with minoxidil in treating alopecia areata (AA). The combination therapy significantly improved hair density and reduced symptoms compared to minoxidil alone. CG’s anti-inflammatory properties help manage AA’s immune response, enhancing the results of minoxidil. The treatment showed a good safety profile, with minimal side effects. However, further high-quality research is needed to confirm the long-term efficacy and safety of this combination.

A new study reveals that patients newly diagnosed with alopecia areata (AA) are at a significantly higher risk of developing autoimmune diseases and psychiatric disorders, including anxiety, depression, and sleep disturbances. Within the first year of diagnosis, around 10.2% of AA patients developed psychiatric conditions, while autoimmune issues like vitiligo, psoriasis, and lupus were also common. Early monitoring and treatment are recommended to prevent long-term complications associated with these comorbidities.

A patchy beard could be more than just a grooming concern, according to experts. Dermatologist Dr. Mary Sommerlad explains that patchy facial hair may signal an underlying health issue like alopecia areata, an autoimmune condition causing circular bald patches. Other causes could include fungal infections, which, if untreated, might lead to permanent hair loss. Additionally, conditions like seborrhoeic dermatitis and eczema can contribute to beard flakiness. If you notice sudden changes, it’s best to consult a healthcare professional for proper diagnosis and treatment.

When treating severe alopecia areata (AA), personalised approaches are crucial. Dr. Kristen Whitney emphasises tailoring treatment based on patient history, severity of hair loss, and previous therapies. Systemic treatments, like JAK inhibitors such as baricitinib and ritlecitinib, have transformed the landscape for severe AA cases, offering hope where options were previously limited. However, these treatments come with potential side effects, including cardiovascular risks. Treatment costs are also high, making affordability a key factor. Doctors must balance the risks and benefits, considering each patient’s unique situation before selecting a treatment plan.

A new AI-driven hair analysis method offers potential breakthroughs in health diagnostics by using hair samples to assess an individual’s overall health. Researchers believe this approach could provide non-invasive insights into nutritional deficiencies, stress levels, and even chronic diseases. By analysing hair at a molecular level, the AI system can detect biomarkers related to various health conditions, giving a clearer picture of a person’s long-term well-being. This innovative method holds promise for personalised healthcare, offering a more accessible and detailed way to monitor and manage health issues.

As hair transplants grow in popularity, it’s essential to be aware of the associated risks. While the procedure is generally safe, potential complications include infection, scarring, and unnatural hair growth patterns. Some patients may also experience “shock loss,” where transplanted hair falls out temporarily. The rise of medical tourism for cheaper procedures abroad raises concerns about unregulated clinics and inexperienced surgeons. Experts advise thorough research, choosing accredited clinics, and considering the long-term financial and health impacts before opting for surgery. Awareness is key to ensuring a safe and successful outcome.

A recent study demonstrated that 2-deoxy-D-ribose (2dDR) stimulates hair regrowth in an animal model of androgenic alopecia. This compound promotes vascular endothelial growth factor (VEGF) production, encouraging blood vessel formation around hair follicles, which is essential for hair regrowth. When tested on mice, 2dDR showed promising results in reversing testosterone-induced hair loss, highlighting its potential as a future therapeutic option for androgenic alopecia. Further research is needed to explore its effectiveness in human trials.

A recent study revealed that diphenylcyclopropenone (DPCP) immunotherapy shows significant promise in treating paediatric alopecia areata (AA). Over 61.8% of patients experienced some hair regrowth, while 8.8% achieved full regrowth after one year of treatment. Factors like the severity of AA and treatment duration influenced results, with patchy alopecia responding more favourably. Minor side effects, such as blisters, were common but manageable. Further research is needed to fully establish DPCP’s efficacy in paediatric AA management.

A recent review highlights how genomic markers, including single-nucleotide polymorphisms (SNPs), are offering insights into androgenetic alopecia (AGA) and paving the way for personalised treatments. By identifying specific genetic variants, researchers aim to improve the effectiveness of medications like minoxidil and finasteride, tailoring therapies based on individual genetic profiles. Emerging techniques such as RNA interference (RNAi) further hold promise for targeting androgen receptors to promote hair growth. These advancements signal a move towards more personalised and effective AGA treatments.

A recent study has shown that concentrated growth factors (CGF) may be a promising treatment for androgenetic alopecia (AGA). Over six months, CGF injections significantly increased hair density and improved patient satisfaction without major side effects. This advanced form of platelet-rich plasma (PRP) therapy could offer a safer, less invasive option compared to traditional treatments like hair transplants or medications. While the early results are promising, larger studies are needed to confirm the long-term efficacy of CGF for AGA.

Alopecia areata (AA) significantly raises the risk of autoimmune conditions like vitiligo, lupus, and thyroid disease, as well as psychiatric disorders such as anxiety and depression. Research shows that AA patients are more likely to develop these conditions both before and after their hair loss diagnosis. This highlights the need for comprehensive care, including mental health support and regular screening for autoimmune diseases, to improve patient outcomes. Early intervention and monitoring are essential for those with AA to manage these risks effectively.

A study investigating the relationship between hypothyroidism and hair loss conditions, including alopecia areata (AA) and androgenetic alopecia (AGA), found a causal link between hypothyroidism and AA. Using Mendelian randomization, researchers concluded that hypothyroidism significantly increases the risk of AA. However, no similar association was found between hypothyroidism and AGA. This emphasises the importance of thorough thyroid assessments in AA patients to ensure accurate diagnosis and treatment​.

A clinical study reveals that adipose-derived stem cell (ASC) exosomes significantly improve hair density in patients with androgenetic alopecia (AGA). The treatment, which involves injecting exosomes into the scalp, showed a notable increase in hair count and thickness after 12 weeks. This research suggests that ASC exosomes could be a promising non-invasive therapy for AGA, offering an alternative to traditional treatments like minoxidil and finasteride.

A bibliometric analysis highlights a significant increase in research on alopecia areata (AA) over the past 20 years. The focus has shifted towards emerging therapies like JAK inhibitors and platelet-rich plasma (PRP). The United States leads in publications, followed by China, with top contributions from institutions like the University of Miami and Columbia University. Despite this progress, the study emphasises the ongoing need for effective, long-term treatments for AA.

A study published in Frontiers in Nutrition reveals that diets rich in antioxidants can significantly reduce the risk of androgenic alopecia (AGA), especially in women, while pro-inflammatory diets increase the risk. The research highlights that metabolic syndrome might mediate the relationship between inflammation and AGA, suggesting that dietary adjustments could be a key strategy in preventing hair loss, particularly for those genetically predisposed to AGA.

An opinion piece argues that men who care about going grey or bald shouldn’t be labelled as vain. Society often trivialises male appearance concerns, but hair loss can significantly impact self-esteem and mental health. The article emphasises that it’s natural for men to care about their appearance and that their concerns deserve recognition and support, just like those of women. Addressing these issues openly can lead to a better understanding and acceptance of men’s experiences with hair loss.

A new study reveals that discontinuing baricitinib, a treatment for severe alopecia areata, leads to hair loss in 80% of patients who had previously seen regrowth. The research emphasises that ongoing therapy is essential to maintain the benefits of baricitinib. The study underscores that alopecia areata is a chronic condition requiring long-term treatment to sustain hair regrowth.

A clinical trial led by the Crnic Institute for Down Syndrome reveals that the JAK inhibitor tofacitinib significantly reduces autoimmune conditions in individuals with Down syndrome. The study observed improvements in skin conditions like alopecia areata, as well as arthritis and autoimmune thyroid disease. The treatment lowered inflammatory markers while maintaining immune function. Although the results are promising, further research is needed to confirm the safety of JAK inhibitors for this population.

Dr. Donald Grant debunks common hair loss myths, emphasising that stress is not the main cause of non-genetic hair loss. While stress can contribute, factors like diet, vitamin deficiencies, and age play significant roles. He highlights that hair loss affects both men and women, often starting as early as the teenage years. Frequent hair washing does not cause hair loss, contrary to popular belief. Early recognition of hair loss signs can lead to better treatment outcomes.

Sulfates, common in many shampoos, are not directly linked to hair loss. However, they can strip natural oils from the scalp, leading to dryness and irritation, which might contribute to hair breakage and thinning in some people. Those with sensitive scalps or already thinning hair might benefit from sulfate-free shampoos, which are gentler and help maintain scalp health. While sulfates aren’t a direct cause of hair loss, choosing the right shampoo can support overall hair health.

A recent study highlights the potential of autologous fat grafting as an innovative treatment for alopecia. The procedure involves injecting a patient’s own fat, enriched with stem cells, into the scalp to stimulate hair regrowth. Early results are promising, with patients showing significant improvements in hair density and scalp health. This approach could offer a new, minimally invasive option for those struggling with hair loss, though further research is needed to confirm long-term effectiveness.

Recent research reveals that individuals with alopecia areata have a higher prevalence of autoimmune diseases, such as thyroid disorders, and psychiatric conditions, including anxiety and depression. The study underscores the need for comprehensive care that addresses both the physical and mental health challenges associated with alopecia. These findings highlight the importance of regular monitoring and holistic treatment approaches for those affected by this hair loss condition.

Swimming can damage your hair and skin due to chlorine, saltwater, and prolonged sun exposure. To protect your hair, consider wearing a swim cap, using a leave-in conditioner, or rinsing hair with fresh water before and after swimming. For skin protection, apply waterproof sunscreen and moisturiser post-swim. These steps help maintain healthy hair and skin while enjoying time in the water.

A recent study highlights that many men with alopecia areata feel their psychosocial support needs are not adequately addressed. The emotional impact of hair loss, including anxiety and low self-esteem, is significant, yet many men do not receive the mental health support they need. The findings suggest that healthcare providers should prioritise holistic care, offering both medical treatments and emotional support to help men cope with the psychological effects of alopecia.

Dr. Natasha Mesinkovska discussed the positive results from phase 3 trials of deuruxolitinib for severe alopecia areata, showing over 30% of patients achieved significant hair regrowth within 24 weeks. This JAK inhibitor, taken orally, targets inflammatory pathways, offering a well-tolerated treatment option with manageable side effects like headaches and acne. Mesinkovska highlighted its impact on patients’ psychosocial well-being and the need for ongoing research.

The FDA has approved deuruxolitinib (Leqselvi) for treating severe alopecia areata, following successful phase 3 trials (THRIVE-AA1 and THRIVE-AA2). Over 30% of patients experienced significant hair regrowth with this twice-daily JAK inhibitor. Common side effects include headaches, acne, and nasopharyngitis, with more serious risks such as infections and thrombosis. This approval marks a significant advancement in managing this autoimmune condition, providing new hope for patients suffering from severe hair loss.

Melatonin does not cause hair loss; in fact, it may help promote hair growth. Topical melatonin, rather than oral supplements, has shown potential in treating hair loss conditions like androgenetic alopecia by protecting hair follicles from oxidative stress and stimulating hair cell growth. While studies suggest that melatonin can halt hair loss and encourage new growth, more research is needed to fully understand its efficacy. It’s essential to consult with a healthcare provider before starting melatonin treatments for hair loss to ensure it’s appropriate for your condition.

A recent study presented at the Society for Pediatric Dermatology Annual Meeting highlighted the effectiveness of dupilumab in treating pediatric alopecia areata (AA) with atopic dermatitis. The study reviewed 31 pediatric patients, revealing that 77.4% experienced significant hair regrowth. Dupilumab, primarily used for atopic dermatitis, appears beneficial due to its immune-modulating effects, addressing the underlying inflammatory pathways common in both conditions. Further research is needed to confirm long-term efficacy and safety.

Recent studies have shown that low-dose oral minoxidil (LDOM) is a safe and effective treatment for various types of alopecia, including in pediatric patients. Research highlights that LDOM, typically used at doses between 0.25 to 5 mg daily, effectively promotes hair growth by shortening the telogen phase and prolonging the anagen phase of hair follicles. Adverse effects are generally mild and include hypertrichosis, lightheadedness, and fluid retention. This makes LDOM a promising option for children who cannot tolerate topical treatments.

Dr. Marissa Joseph emphasized the importance of proper diagnosis and management of scarring alopecia in adolescents at a recent dermatology conference. Highlighted conditions included central centrifugal cicatricial alopecia (CCCA), which often affects Black females. Diagnosis relies on trichoscopy and histopathology. Treatment involves anti-inflammatory medications and educating patients on gentle hair care practices. Joseph stressed avoiding premature diagnostic closure, as proper identification and management can prevent permanent hair loss and improve patient outcomes.

Researchers from the University of Sheffield and COMSATS University Pakistan have discovered that 2-deoxy-D-ribose (2dDR), a naturally occurring sugar, can stimulate hair regrowth in mice. This sugar promotes new blood vessel formation, leading to hair regrowth similar to the effects of Minoxidil, a current hair loss treatment. The findings suggest a potential new treatment for male pattern baldness, affecting up to 50% of men worldwide, by enhancing blood supply to hair follicles. Further investigation is needed to confirm these promising early results.

A recent study highlights a significant link between seasonal and food allergies and an increased risk of developing alopecia areata (AA). The research, published in the European Journal of Allergy and Clinical Immunology, utilized Mendelian randomization to explore this association. The findings reveal that allergies, including hay fever, eczema, asthma, and reactions to pollen, dust mites, and cats, significantly elevate AA risk. This suggests that the inflammatory responses triggered by these allergies may play a crucial role in AA’s pathogenesis. Early monitoring and integrating patient allergy history into AA management could improve treatment outcomes.

A recent study has revealed that individuals with alopecia, including scarring and non-scarring types, have lower rates of substance use disorder (SUD) compared to the general population. Researchers analyzed data from the All of Us Research Program and found that among 9,385 alopecia patients, only 8.4% had SUD. This suggests that alopecia might act as a protective factor against substance abuse, possibly due to heightened health awareness and more frequent medical interactions. These findings emphasize the importance of comprehensive health monitoring for alopecia patients.

A Spanish dermatology expert consensus provides updated guidelines for managing androgenetic alopecia (AGA). The recommendations emphasize individualized treatment plans, incorporating oral and topical minoxidil, 5-α-reductase inhibitors, and advanced techniques like mesotherapy and low-level laser therapy. For both men and women, oral minoxidil emerged as a preferred first-line treatment. The consensus also underscores the importance of adherence to long-term treatment for effectiveness and highlights the need for thorough diagnosis and patient-specific strategies.

A study led by Dr. Barbara Burgos-Blasco discovered a connection between alopecia areata and corneal abnormalities, potentially due to systemic inflammation. The research compared 25 patients with alopecia areata to 29 controls, finding significant differences in corneal sensitivity, staining, and biomechanical parameters. The findings suggest a higher incidence of corneal ectasia in affected patients. The study recommends comprehensive ophthalmologic examinations and prolonged follow-ups for early diagnosis and prevention of ocular morbidity in patients with severe alopecia areata.

Inflammatory hair disorders, especially scarring alopecias, pose significant challenges in pediatric dermatology. Dr. Marissa Joseph’s presentation at the 2024 Society for Pediatric Dermatology highlighted the complexities of diagnosing and treating these conditions. Early diagnosis using tools like biopsies is crucial. A case study of central centrifugal cicatricial alopecia (CCCA) underscored the importance of accurate diagnosis and tailored treatment. Scarring alopecias often require multifaceted approaches, emphasizing the need for further research and comprehensive care strategies for affected children.

A recent study compared the efficacy and safety of oral and topical minoxidil in treating male androgenetic alopecia (AGA). Conducted on men aged 18-55, the trial found no significant differences in hair density improvements between the two methods. However, photographic analysis showed oral minoxidil was superior in the vertex scalp area. Common side effects for oral minoxidil included hypertrichosis and headaches. Overall, both treatments were similarly effective, highlighting the need for further research to determine optimal AGA treatment strategies.

Red light therapy scalp massagers are emerging as a promising tool for combating hair loss. Combining light therapy with massage, these devices aim to stimulate blood flow and hair follicle activity, potentially promoting hair growth. Red light therapy is believed to enhance cellular function and repair, making it a popular choice for those experiencing thinning hair. While clinical evidence is still developing, many users report positive results, integrating this non-invasive treatment into their hair care routines.

Recent studies suggest a potential link between COVID-19 vaccines and the onset or recurrence of alopecia areata (AA). Researchers reviewed 51 cases, noting that 45.1% were linked to the Pfizer vaccine. Symptoms ranged from patchy AA to more severe forms like alopecia universalis. Treatments included corticosteroids and JAK inhibitors, with varying outcomes. Individuals with a history of AA or thyroid issues might be at higher risk. Dermatologists are advised to monitor symptoms post-vaccination closely.

Alopecia Areata (AA) often affects nails, presenting symptoms like pitting, ridging, and white spots, which can precede or follow hair loss. The condition impacts quality of life and psychological well-being due to its unpredictable nature. Diagnosis involves biopsies and high-frequency ultrasonography, while management focuses on symptom severity. Treatments range from topical applications to systemic corticosteroids, though evidence-based approaches are limited. Emerging therapies, like JAK inhibitors, show promise.

A recent study explores the link between immune cells and non-scarring hair loss (NSHL). Researchers conducted a Mendelian randomization analysis using data from the IEU Open GWAS Project. They identified 31 immune cell phenotypes associated with NSHL: 19 showed protective effects, while 12 were positively correlated. These findings highlight the immune system’s role in NSHL, suggesting new directions for immune-based therapies. The study underscores the importance of specific immune cells in developing effective treatments for NSHL.

A recent survey reveals that dermatology residents feel less comfortable treating hair issues in patients with skin of color (SOC). Among 121 residents surveyed, those from underrepresented backgrounds reported higher comfort levels, particularly in managing afro-textured hair. The study suggests that increased diversity in residency programs and enhanced education on SOC hair care can bridge these comfort gaps, improving patient care. Despite some improvements, overall comfort levels remain suboptimal, indicating a need for more comprehensive training in this area.

Ozempic (semaglutide), a medication for type 2 diabetes, is not directly linked to hair loss. However, rapid weight loss, a common effect of the drug, can cause a condition called telogen effluvium, which leads to temporary hair shedding. Nutritional deficiencies and hormonal changes associated with weight loss and diabetes management might also contribute to hair thinning. It’s important for patients experiencing hair loss to consult their healthcare provider to address any underlying issues and consider treatment options such as nutritional supplements or topical treatments.

Recent research highlights that minoxidil, commonly used for hair regrowth, provides only modest benefits for patients with alopecia areata. Studies indicate that while minoxidil can stimulate hair growth, its effectiveness varies significantly. Approximately 38% of patients using 1% minoxidil and 81% using 5% minoxidil experienced some hair regrowth. However, its benefits are less pronounced in severe cases such as alopecia totalis or alopecia universalis. Continued use is necessary to maintain any hair regrowth achieved, and side effects can include dermatitis and unwanted hair growth in non-target areas​.

Researchers at the University of Manchester have discovered that inhibiting the integrated stress response (ISR) could help prevent hair loss. The ISR, an ancient biological reaction to stress, can halt hair growth by stopping cell division in hair follicles. In a study published in PLOS ONE, scientists found that blocking ISR activation might maintain hair growth and treat conditions like alopecia. Further research is needed to confirm these findings and develop effective treatments.

A recent study highlights that cysteine deficiency may contribute to hair breakage in patients with alopecia areata (AA). Researchers found that disruptions in cysteine metabolism can lead to weaker hair, making it more prone to breaking. This connection suggests that targeting cysteine levels and metabolism might offer new therapeutic approaches for AA treatment, potentially improving hair strength and reducing breakage.

Researchers are exploring the use of thyroid receptor β (TRβ) agonists as a novel treatment for androgenetic alopecia (AGA). TRβ agonists may promote hair growth by activating the Wnt/β-catenin and Sonic hedgehog signaling pathways. These pathways are crucial for hair follicle development and regeneration. Early studies on TRβ-specific drugs, like KB-141 and MGL-3196, show promise, but further research is needed to fully understand their efficacy and safety for AGA treatment.

A study at King Abdulaziz Medical City, Riyadh, reveals that nearly 76.4% of psoriasis patients also suffer from autoimmune diseases, notably hypothyroidism and alopecia areata. The research indicates a significant correlation between psoriasis and autoimmune disorders, emphasizing the need for integrated management strategies. This highlights the complex immune-mediated processes involved in psoriasis, suggesting further investigation into associated autoimmune conditions is necessary.

A new study using ultraviolet-induced red fluorescence dermoscopy (UVFD) has highlighted significant microbial composition differences in patients with androgenetic alopecia (AGA). Researchers found variations in microbial evenness and abundance across different scalp regions. The study suggests red fluorescence could indicate inflammation around miniaturized hair follicles in AGA, opening potential avenues for new diagnostic and treatment methods. The findings emphasize the role of scalp microbiota in hair health and call for further exploration into fluorescence-based diagnostic techniques.

Researchers at the University of Manchester have discovered that the Integrated Stress Response (ISR), an ancient cellular mechanism, plays a significant role in restricting hair growth. The study, initially aimed at stimulating hair follicle stem cells, found that the ISR activation instead halted hair growth by disrupting cell division and mitochondrial function. This discovery could lead to new treatments for hair loss by targeting this pathway, potentially offering hope for those with hair loss conditions.

A European expert consensus has identified promising new treatments for alopecia areata (AA). Key options include combination therapies and targeted biologics, which have shown significant potential in hair regrowth and improving patients’ quality of life. Systemic therapies like oral glucocorticosteroids, cyclosporine, methotrexate, and the latest JAK inhibitors, such as baricitinib and ritlecitinib, are highlighted. The report emphasizes personalized treatment plans considering individual patient characteristics.

A young man with androgenetic alopecia experienced a topical minoxidil overdose, leading to severe complications. Symptoms included dizziness, low blood pressure, and rapid heart rate. The patient was hospitalized and treated with fluids and beta-blockers. This case highlights the potential dangers of improper minoxidil use and underscores the need for medical supervision when using hair loss treatments.

Equillium’s Phase 2 study reveals that EQ101, a multi-cytokine inhibitor, is both effective and well-tolerated for treating alopecia areata, an autoimmune condition causing hair loss. The study included 36 adults with significant hair loss, demonstrating that 20% of participants achieved notable hair regrowth with SALT scores ≤20 after 24 weeks. EQ101 was administered intravenously weekly and showed improvements across various severity levels of the condition. Equillium plans further studies to optimize dosing and delivery methods, aiming to expand treatment options for this challenging condition.

A study from King’s College London, published in JAMA Dermatology, indicates that the use of oral contraceptives may contribute to frontal fibrosing alopecia (FFA), a type of scarring hair loss. Researchers found that women with a specific version of the CYP1B1 gene, which metabolizes hormones, are more prone to FFA if they use oral contraception. The study highlights the gene-environment interaction in FFA development and suggests the potential for genetic testing to mitigate risk.

A recent systematic review explores mesotherapy as a promising alternative to minoxidil for treating androgenetic alopecia. Mesotherapy involves injecting hair growth-promoting substances directly into the scalp, showing significant potential in improving hair density and quality. The review suggests mesotherapy could offer comparable, if not superior, results to minoxidil, with fewer side effects. This innovative approach provides a new avenue for those struggling with hair loss, offering a potentially more effective and safer treatment option.

Elithair’s note: Are you suffering from hair loss, but feel like you’re not ready to treat it wirth a surgery or medications ? Try our mesotherapy kit today!

A recent study found that Platelet-Rich Plasma (PRP) therapy can enhance hair regrowth in patients with androgenetic alopecia (AGA) and potentially rebalance the scalp microbiome. The study, conducted on 14 participants, revealed significant hair growth and changes in the scalp’s microbial composition after six months of treatment. While the exact link between microbiome balance and hair growth requires further investigation, these findings suggest that PRP therapy could be a promising alternative to current FDA-approved AGA treatments.

For more details, read the full article here.

A study published in “ScienceDirect” investigates the efficacy of certain herbal extracts in treating hair loss. The research focuses on the biological activity of these extracts, their potential in promoting hair growth, and how they compare to conventional treatments. This study provides a scientific foundation for using herbal remedies as a viable alternative to traditional hair loss treatments, highlighting specific herbs that show promising results in stimulating hair regeneration.

A recent study featured in AJMC suggests that individuals with allergies, such as hay fever, eczema, asthma, and allergies to pollen, dust, and cats, have a significantly higher risk of developing alopecia areata, an autoimmune condition causing hair loss. This research utilized genetic data to explore how these allergic conditions might influence alopecia development, pointing to an increased need for personalized treatment approaches based on a patient’s allergic profile.

The article in “ScienceDirect” delves into the complexities of androgenetic alopecia, a common form of hair loss. It discusses recent advancements in understanding the genetic and environmental factors contributing to this condition. The study also explores potential new treatments that target these factors, aiming to provide more effective solutions for those affected. This research is crucial for developing future therapies that could prevent or reverse hair loss.

A recent study in the “Dermatology Times” highlights the barriers that limit access to JAK inhibitor therapy for alopecia areata, particularly among non-white patients. The findings reveal obstacles such as high costs, insurance issues, and inadequate provider awareness, leading to disparities in treatment. Researchers call for improved insurance coverage, greater awareness among healthcare providers, and addressing the unique challenges faced by minority groups to enhance access to this effective treatment .

Research discussed in “The Conversation” emphasizes the importance of taking male baldness seriously, beyond cosmetic concerns. It often leads to psychological distress due to societal trivialization. The article advocates for greater awareness and supportive measures, highlighting that baldness can significantly affect men’s mental health and self-esteem. This perspective encourages a shift in how baldness is viewed and managed in society.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued a new warning for the hair loss drug finasteride, highlighting serious potential side effects including suicidal thoughts and sexual dysfunction. The alert advises users and healthcare providers to be vigilant for symptoms affecting mental health and sexual function. The packaging for finasteride will now include a safety alert to increase awareness among users about these risks. The decision follows reports of adverse effects and aims to improve patient information and safety.

This article emphasizes proactive measures to tackle hair loss effectively. Recommending early intervention, it underscores the significance of seeking professional guidance at the first signs of hair thinning. Dermatologists advocates for a holistic approach, emphasizing the role of nutrition, stress management, and targeted treatments tailored to individual needs. Addressing common misconceptions, she highlights the importance of understanding underlying causes and customizing treatment plans for optimal results. Her expert advice aims to empower individuals in the UK to take proactive steps in preserving hair health and confidence.

Elithair’s note: Are you also suffering from hair loss? Our experts are at your disposal for a free and non-binding consultation

A recent review highlighted potential adverse effects of semaglutide, a medication used to treat type 2 diabetes and obesity, including altered skin sensations and alopecia. The analysis found that patients taking semaglutide may experience a higher incidence of these issues. While semaglutide has shown effectiveness in managing diabetes and weight loss, it’s essential for patients to be aware of possible side effects, particularly those related to hair and skin. This information underscores the importance of healthcare providers monitoring patients closely for any signs of skin sensation changes or hair loss while on semaglutide therapy.

A study investigates the association between baseline salt scores and the severity of alopecia, along with its impact on patient quality of life (QoL). Researchers found that higher baseline salt scores were significantly correlated with increased severity of alopecia and poorer patient QoL. This suggests a potential role of salt in the pathogenesis of alopecia and its impact on patients’ well-being. Understanding this association could aid in developing targeted interventions to improve both the management of alopecia and the overall QoL of affected individuals.

The Independent’s article explores the correlation between climate change and women’s hair loss in Bangladesh. It reveals that rising temperatures and increased humidity have led to a surge in hair loss cases among women in rural areas. Environmental stressors are identified as the primary cause, affecting hair follicles adversely. Urgent action is recommended to tackle this issue, with a focus on climate resilience strategies and sustainable development efforts. The article underscores the broader concerns surrounding environmental degradation and its repercussions on human well-being, particularly in vulnerable communities like those in Bangladesh.

A recent review published in The American Journal of Managed Care reveals that Janus kinase (JAK) inhibitors demonstrate superior effectiveness in treating moderate to severe cases of alopecia areata (AA) compared to conventional therapies. The review examined data from clinical trials, showcasing the potential of JAK inhibitors to stimulate hair regrowth in patients with AA, a condition affecting thousands in the UK. This breakthrough offers hope for individuals struggling with hair loss, indicating a promising avenue for future treatments tailored to UK patients combating this distressing condition.

The article discusses the burgeoning expansion of the hair transplant instruments market and its significant role in advancing hair restoration solutions. It highlights key factors driving market growth, including technological advancements and increasing demand for aesthetic procedures. The report emphasizes the rising adoption of minimally invasive techniques and innovative instrumentation in hair transplant procedures. With a focus on market dynamics and future projections, the article provides valuable insights into the evolving landscape of hair transplantation, indicating a promising trajectory for the industry’s expansion and its impact on addressing hair loss concerns.

A recent study published in the Journal of Investigative Dermatology suggests a novel approach to combating hair loss. Researchers from the University of Manchester identified a specific protein, FGF9, that plays a crucial role in hair follicle growth. By manipulating this protein, they were able to stimulate hair growth in lab mice. This discovery holds promise for future hair loss treatments, offering hope to millions affected by alopecia and other conditions. While further research is needed to validate these findings in humans, this breakthrough marks a significant step forward in the fight against hair loss.

Delve into the depiction of women’s hair loss in art throughout history. This insightful article from The Conversation explores various interpretations of alopecia in art, highlighting the diverse ways hair loss has been portrayed and symbolized. From ancient sculptures to contemporary paintings, the piece examines cultural, social, and personal meanings attributed to hair loss in artistic representations. Gain a deeper understanding of the intersection between aesthetics, identity, and hair loss perceptions through an engaging exploration of artworks spanning different eras and cultures.

What is the intricate relationship between diet, lifestyle, and hair growth? This article highlights the crucial role of essential nutrients like vitamins, minerals, and proteins in maintaining healthy hair follicles. Additionally, lifestyle factors such as stress, smoking, and sleep patterns are discussed for their significant impact on hair health.

By emphasizing the importance of a balanced diet and healthy lifestyle choices, the article offers valuable insights into practical adjustments that can promote optimal hair growth and prevent hair loss. It provides a comprehensive understanding of how diet and lifestyle choices directly affect hair health, offering readers actionable strategies for maintaining vibrant hair.

AJMC’s article explores the differing viewpoints between patients and physicians regarding the severity of alopecia areata (AA) and treatment satisfaction. It highlights findings from a survey that revealed discrepancies in perceptions of AA severity and satisfaction with treatment outcomes.

While patients often perceive AA as more severe than physicians, satisfaction with treatment varies. Understanding these differences is crucial for improving communication and aligning treatment goals between patients and healthcare providers. This study sheds light on the importance of addressing patient concerns and preferences in managing AA effectively.

This article from Medriva offers a comprehensive guide to selecting the right shampoo for thinning hair and hair loss. It covers key factors to consider, such as ingredients like biotin and ketoconazole, and their effectiveness in promoting hair growth. Additionally, it provides tips on avoiding harsh chemicals, choosing sulfate-free options, and understanding the role of scalp health in hair growth.

Elithair’s notes: Did you know that our lead surgeon Dr. Balwi has developed a range of hair care products? Those includes shampoos and sprays rich in biotin, all available in our shop.

A groundbreaking drug for treating alopecia has been recommended for NHS use for the first time. The drug, called ruxolitinib, has shown promising results in clinical trials, offering hope to millions suffering from hair loss. Ruxolitinib works by inhibiting a protein linked to alopecia, potentially providing an effective treatment option for both men and women. If approved, this recommendation could mark a significant milestone in addressing alopecia and improving the quality of life for those affected.

This article discusses recent advancements in psoriasis treatments, highlighting innovative therapies such as biologics and small molecules. These treatments target specific immune pathways involved in psoriasis development, providing more effective and targeted options for patients. The article explores the benefits and limitations of these treatments, emphasizing the importance of individualized care and ongoing research in improving outcomes for psoriasis patients.

This article highlights a study revealing a significant correlation between smoking and the risk of androgenetic alopecia (AGA) in men. Researchers found that smoking is associated with a higher likelihood of developing AGA, independent of age and other factors. The study emphasizes the importance of smoking cessation interventions in reducing the risk of AGA. Understanding this association can aid in early prevention and intervention strategies for AGA in men.

This article discusses a new consensus on evaluating alopecia, emphasizing standardized terminology and assessment methods. Experts from various fields collaborated to create guidelines for diagnosing and managing alopecia more effectively. The consensus aims to improve communication among healthcare professionals and enhance patient care. It highlights the importance of a multidisciplinary approach and ongoing research to address the complexities of alopecia.

This article from Medscape provides insights into identifying and treating various causes of hair loss in children. It covers different conditions such as alopecia areata, tinea capitis, and telogen effluvium, discussing their symptoms, diagnosis, and treatment options. From autoimmune disorders to fungal infections, the piece offers a comprehensive overview to help parents and healthcare professionals recognize and manage hair loss in children effectively.

This article delves into the post-COVID risk for alopecia areata, shedding light on new insights and implications. It explores the potential link between COVID-19 and the onset of alopecia areata, discussing factors such as stress and immune system response. The piece emphasizes the importance of understanding this connection for effective management and treatment.

The article discusses a breakthrough in hair growth research, highlighting a novel technique utilizing low-intensity pulsed ultrasound (LIPUS). Researchers have successfully stimulated hair growth in mice by applying LIPUS for just 20 minutes a day. The method has shown promising results in increasing hair density and thickness, sparking hope for future applications in treating hair loss.

The Food and Drug Administration (FDA) is investigating reports of side effects from diabetes medications like Ozempic and Mounjaro. These drugs are in a class called GLP-1 receptor agonists, which are also used for weight loss. The FDA is “evaluating the need for regulatory action”. Novo Nordisk, the company that makes Ozempic, said the known risks associated with the drug are reflected in its label.

According to the recent report featured on GlobeNewswire, the global hair transplant market is projected to soar to USD 38.8 billion by 2032. The surge is attributed to a rising demand for aesthetic solutions worldwide. The article outlines key factors fuelling this growth and provides insights into the evolving landscape of hair restoration procedures.

A new study has found that people who have had COVID-19 are more likely to develop alopecia areata, a type of hair loss that causes round patches of hair to fall out. The study also found that the risk of telogen effluvium, another type of hair loss, was increased after COVID.

The authors of the study believe that there are a few possible explanations for this link, including that COVID may trigger the immune system to attack hair follicles. They also say that more research is needed to confirm this link and to determine the best way to treat alopecia areata after COVID.

Discover the intricate link between thyroid health and hair loss in the UK on Medriva’s latest article. The piece explores the potential role of thyroid dysfunction in hair loss and provides insightful information on conquering this common issue. Gain valuable insights into how understanding your thyroid’s impact on hair health can be a crucial step towards effective prevention and management.

This article from Medriva delves into the intricate relationship between genetics, hormones, and chemotherapy on hair growth and loss. Our hair’s texture, thickness, and color are primarily determined by our genes, while hormones play a crucial role in regulating hair growth cycles. Fluctuations in hormones during puberty, pregnancy, and menopause can lead to noticeable changes in hair. Chemotherapy, a treatment for cancer, can also induce hair loss. Additionally, age-related hormonal changes can contribute to hair thinning. Greying hair, a natural part of aging, is attributed to the reduced function of melanin-producing cells. Researchers at the University of Wollongong are making significant progress in hair regrowth research.

A recent article on Dermatology Times highlights a significant correlation between smoking and the accelerated progression of male pattern hair loss. The study reveals that individuals who smoke cigarettes face higher odds of experiencing more advanced stages of hair loss. This crucial insight sheds light on a previously underestimated factor in hair health.

The latest research covered in AJMC explores a promising development for individuals with severe alopecia areata. The study reveals that regrowth of hair in severe cases not only enhances quality of life but also reduces anxiety and depression. The findings underscore the psyhcological impact of regaining hair in those battling this autoimmune condition.

The article on AJMC sheds light on the disparities in clinical trial enrolment and retention among marginalized racial and ethnic groups facing alopecia areata. Examining the challenges these communities encounter, the piece emphasizes the importance of inclusive research practices to enhance understanding and treatment options for diverse populations.